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ABSTRACT 
SYNOVIAL FIBROSIS IN OSTEOARTHRITIS OF THE KNEE: MECHANISM OF 
DEVELOPMENT AND POTENTIAL THERAPEUTIC TARGETS 
by Marwa Qadri  
 
Synovial tissue fibrosis is an immune mediated disease characterized by fibroblast cell migration, 
proliferation and transition to a myofibroblast phenotype characterized by alpha smooth muscle 
actin (a-SMA) upregulation and stress fiber formation. Transforming growth factor-β (TGF-b) 
plays an important role in mediating the pathogenesis of synovial fibrosis. Synoviocytes produce 
proteoglycan-4 (PRG4; lubricin), a heavily glycosylated mucinous glycoprotein, and hyaluronic 
acid (HA). Both PRG4 and HA compete for binding to the CD44 receptor. Furthermore, rhPRG4 
binds to TLR2 and TLR4 and acts as an antagonist to prevent TLR2 and TLR4 activation by 
bacterial ligands. In this work, we aimed to investigate the role of CD44 receptor and its ligands 
HA in regulating the activation of macrophages in response to TLR2 receptor stimulation in the 
context of an acute inflammatory response and study the impact of increasing intracellular cyclic 
adenosine monophosphate (cAMP) in OA fibroblast-like synoviocytes (OA-FLS) on regulating 
TGF-β linked expression of fibrotic genes and the contribution of PRG4 and HA to this effect. 
Also, we studied the significance of PRG4-CD44 interaction in mediating fibroblast to 
myofibroblast transition in vitro and regulation of synovial fibrosis in vivo.  In the first manuscript, 
we found that anti-CD44 antibody and HA treatments reduced TLR2 induced-NF-κB nuclear 
translocation, IL-1β and TNF-α expression, and production by human macrophages. In the second 
 
 VIII 
manuscript, we have shown that forskolin (10µM) increased intracellular cAMP levels and 
reduced TGF-β 1-stimulated COL1A1, a-SMA, and TIMP-1 expression in OA synoviocytes. 
Forskolin treatment increased HA secretion and PRG4 expression and production. Moreover, HA 
and PRG4 reduced a-SMA expression and content, and PRG4 reduced COL1A1 expression and 
procollagen I content in OA synoviocytes. In the third manuscript, we found that rhPRG4 was 
internalized by OA synoviocytes via CD44 and rhPRG4 reduced the number of stress fiber-
positive myofibroblasts and cell migration in TGF-b treated NIH3T3 fibroblasts. Synovial tissues 
of 9-months old Prg4GT/GT animals had higher a-SMA, collagen type-I and PLOD2 content and 
Prg4 re-expression reduced these markers. In conclusion, innate immune signals trigger 
macrophage activation which results in synovial inflammation. Ligand-CD44 interactions reduced 
the extent of innate immune-mediated macrophage activation and downstream fibroblasts’ 
response to TGF-b signals from immune cells. rhPRG4 may have potential therapeutic 
applications in mitigating synovitis and synovial fibrosis in advanced OA.  
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1 CHAPTER 1 
INTRODUCTION 
 
1.1 Pathogenesis of osteoarthritis (OA) 
Osteoarthritis (OA) is a degenerative joint disease affecting the synovium, articular cartilage and 
underlying bone [1].  OA is the most prevalent arthritic disease and a leading cause of disability 
in the elderly [1].  OA affects approximately 37.4% of adults aged 60 years or older in the United 
States [2]. The prevalence of  OA is on the rise and is thought to affect more than 50 million people 
in the United States by the year 2020 [3].  Prevalence of OA in males is lower compared with 
females who tend to have a severe form of OA in age 55 and older [4].  Affected joints include 
knees, hips, hands as well as the spine [1].  Several risk factors have been associated with OA, 
including genetic predisposition, advanced age, female sex, obesity and joint trauma [4].  
OA is a multifactorial disease affecting the whole joint [3].  Irreversible loss of articular cartilage, 
inflammation of the synovial membrane, and bone osteophytes are common features of OA [5].  
A complex network of risk factors, mechanical, and biochemical parameters, including cytokines 
and proteolytic enzymes determine the predominance of destructive processes [4, 6, 7].  Articular 
cartilage is a highly specialized connective tissue and is made up of extracellular matrix (ECM) 
(collagen and proteoglycans) and chondrocytes [8, 9]. Chondrocytes are responsible for the 
synthesis and breakdown of the ECM and the balance of chondrocytes’ anabolic and catabolic 
processes is regulated by proinflammatory cytokines and growth factors [9]. Cytokines which have 
an impact on articular cartilage metabolism are classified in three groups including, catabolic (IL-
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1β, TNF-α), regulatory (IL-6, Il-8, IL-4, IL-10, IFNγ) and anabolic (growth factors e.g.TGF-β) [1, 
10]. In OA, the balance of cartilage homeostasis is shifted towards cartilage degradation.  The 
prevailing theory of pathogenesis in OA is that cartilage breakdown products trigger the activation 
of synovial macrophages causing the release of proinflammatory cytokines, like TNF-α, IL-1 and 
IL-6. These cytokines can bind to their chondrocyte receptors leading to further release of 
metalloproteinases and increase cartilage degradation [2].   
The synovium is a soft tissue comprised of a surface layer, the intima, and an underlying subintima. 
The intima of normal synovium is one to three cell layers thick, with two cell types: fibroblast-like 
synoviocytes and macrophages, while the subintima includes blood and lymphatic vessels [8]. The 
synovium is responsible for the maintenance of synovial fluid by producing lubricin and 
hyaluronic acid [11]. Synovial tissue inflammation (synovitis) is a prominent feature contributing 
to OA progression. Histological changes that occur in synovium during synovitis include 
hyperplasia of the lining cell layer, infiltration of inflammatory cells e.g. lymphocytes and 
monocytes, and subintimal fibrosis [1, 2, 12]. Synovitis may be initiated by an innate immune 
response by synovial lining macrophages due to the release of damage associated molecular 
patterns (DAMPs) from articular cartilage and thus perpetuating the inflammation of the synovial 
membrane by synthesis of inflammatory mediators [1, 11] (Fig.1.1). Both synoviocytes and 
osteoarthritic chondrocytes produce large quantities of matrix metalloproteinases (MMPs), e.g. 
MMP-1, MMP-3, MMP-9 and MMP-13, and proinflammatory cytokines (IL-1β, IL-6, TNF-α), 
which mediate disease progression and pain associated with OA [10, 13].  Accumulating evidence 
show that ADAMTS4 (a disintegrin-like and metalloproteinase with thrombospondin type 1 
motifs), is induced upon stimulation of chondrocytes and bovine cartilage explants with IL-1β [13, 
14]. ADAMTS is family of proteins that involved in cartilage degradation in OA. Clinical 
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investigations have revealed that patients with articular cartilage destruction had elevated MMP-
13 and ADAMTS4 expressions [2]. Moreover, transgenic mice with MMP-13-overexpression 
show articular cartilage destruction, suggesting that increased MMP-13 may be the cause of 
cartilage degradation [15, 16].  Furthermore, double knockout of the ADAMTS4 and ADAMTS5 
genes prevents articular cartilage erosion in mice [14, 17]. These findings indicate that MMP-13 
and ADAMTS4 play a crucial role in the progression of OA, and these enzymes could be potential 
targets in OA treatment.  
Macrophages are the most common infiltrating immune cells that are present in inflamed synovial 
tissue [18, 19]. Synovial macrophages play an important role in driving OA pathogenesis due to 
their significantly higher production of inflammatory and catabolic mediators, resulting in 
cartilage degeneration, synovial thickening, and osteophyte formation [19]. In addition to synovial 
tissue macrophages, infiltrating monocytes/macrophages may contribute to OA pathogenesis [18]. 
Current non-surgical treatment options focus on symptoms alleviation and these treatments don’t 
modify the course of the underlying disease. Nonsteroidal anti- inflammatory drugs (NSAIDs) are 
the mainstay for moderate to severe OA [20]. Intra-articular injections of corticosteroids for acute 
inflammation or hyaluronic acid for persistent OA have also been shown to be effective in patients 
with OA [20].  Nonetheless, no disease-modifying anti-osteoarthritis drugs (DMODs) are currently 
available.  
1.2 Function of Proinflammatory and Anti-inflammatory cytokines in OA pathogenesis 
IL-1β is a very low molecular weight soluble peptide, produced and secreted in an inactive form, 
pro-IL-1 [10, 13].  IL-1 β exists in two isoforms: IL-1alpha (IL-1 α) and IL- 1beta (IL-1β).  IL-1β 
is one of the most important proinflammatory cytokines that mediates ECM degradation and joint 
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inflammation in OA[10]. Its role has been identified in the late 1970s as inflammatory mediator to 
mimic the osteoarthritic condition on cultured chondrocytes and synovial cells [13]. Previous 
studies have shown that IL-1β receptor expression was elevated in human OA chondrocytes and 
synovial fibroblasts compared to normal cells [10]. Binding of IL-1β to it specific cell-surface 
receptor IL-1 receptor type I (IL-1RI) initiates a signaling cascade leading to the activation of 
transcription factors, such as nuclear factor kappa B (NF-κB) and interferon regulatory factors 
(IRFs) [21]. This signaling pathway results in a variety of cellular responses including the 
production of pro-inflammatory cytokines and chemokines, downregulation of the synthesis of 
major ECM components by inhibiting anabolic activities of chondrocytes and stimulation of 
chondrocytes and synovial cells to release MMPs and aggrecanases [10, 13]. Other  
proinflammatory cytokines that are involved in OA include TNFα, IL-6 and IL-17 (Fig.1.2). These 
cytokines have been demonstrated to block chondrocytes’ synthesis of type II collagen and 
proteoglycan and promote the production of MMPs enzymes [10].  
TGF-b belongs to a large family of growth factors with an established role in controlling cell 
growth, proliferation, differentiation [22].  There are three isotypes of TGF-b, called β1, β2 and 
β3 [22]. TGF-b plays an essential role in maintaining homeostasis in healthy joints. TGF-β is 
secreted as an inactive complex comprised of propeptide LAP (latency associated peptide) and 
LTBP (latent TGF-β binding proteins [22, 23]. Activated TGF-β binds to the TGF-β type II 
receptor to form a complex that recruits the TGF-β type I receptor, which is activated by 
phosphorylating serine/threonine kinase receptors [23]. TGF-β signaling is initiated with ligand-
induced phosphorylation of the cytoplasmic signaling molecules Smad2 and Smad3 [23].  
Phosphorylated Smad2/3 form a complex with signaling transducer Smad4 and translocate to the 
nucleus resulting in cell-state specific modulation of transcription [23]. TGF-β can also activate 
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Erk, Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways 
[23] (Fig.1.3). TGF-b1 plays an important role in the induction of chondrogenesis and enhancing 
collagen synthesis [24]. Intra-articular injection of low-dose TGF-b1 increases proteoglycan 
content of articular cartilage in mouse knee joints [25]. However, overexpression of TGF-β1 in the 
knee joint results in OA-like changes, including hyperplasia and synovial fibrosis [26].  
1.3 Role of the Toll-like Receptors (TLRs) in OA pathogenesis  
TLRs are large family of receptors that belong to the family of pattern recognition receptors 
(PRRs) [27, 28]. There are at least 11 members of TLRs that have been identified thus far [27].  
TLRs play a vital role in host defenses by recognizing pathogen-associated molecular patterns 
(PAMPs), including cell wall components of bacteria, viruses and fungi [29]. TLRs are also 
stimulated by DAMPs, and endogenous danger signal molecules that are released from injured 
cells [27, 29]. Examples of DAMPs that were shown to activate TLRs in the joint environment 
include biglycan, fibronectin and low molecular weight hyaluronan fragments, and insoluble 
crystals e.g. monosodium monohydrate urate and calcium phosphate crystals [30-33]. Activation 
of TLRs by DAMPs initiates a signaling cascade leading to the activation of transcription factors, 
such as NF-κB [34, 35]. This signaling pathway results in a variety of cellular responses including 
the production pro-inflammatory cytokines and chemokines [35] (Fig.1.4).TLRs are 
transmembrane receptors characterized by an extracellular domain and a cytoplasmic Toll/IL-1 
receptor (TIR) domain that initiates downstream signaling [35]. Cell surface TLRs include TLR1, 
TLR2, TLR4, TLR5, TLR6 and TLR10 and they mainly recognize microbial components like 
lipopolysaccharides [36]. Endosomal TLRs include LR3, TLR7, TLR8 and TLR9 and they 
recognize nucleic acids derived from bacteria and viruses [36].  
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The role of TLRs in OA pathogenesis has been studied.  Chondrocytes derived from a TLR2/TLR4 
double knockout mice resisted the pro-catabolic effect of low molecular weight hyaluronan and 
showed attenuated MMP-13 expression [37].  Furthermore, TLR2 and TLR4 can act 
synergistically to increase inflammatory cytokine production in OA synovial cells [38]. Early 
reports showed that synovial fluid (SF) from patients with early OA augments synoviocytes 
responses to TLR2 and TLR4-ligands and that plasma proteins present in OA SF stimulate 
cytokine production in a TLR4-dependent manner [39]. Additionally, it has been recently observed 
that OA SF activates TLR2 and TLR4 on human embryonic kidney cells [40].   
Moreover, the role of innate immune system in mediating tissue remodeling and fibrosis has been 
highlighted in a number of studies. Recent studies showed that activation of TLR4 sensitizes skin 
fibroblasts to the stimulatory effect of TGF-b1 and enhances the accumulation of ECM molecules 
[41]. Moreover, fibroblasts isolated from TLR4-/- mice showed attenuated profibrotic activities of 
TGF-b1, suggesting the innate immune signaling via TLRs are essential for fibroblast activation 
[41]. Interestingly, synovial resident cells have been shown to express TLRs and persistent 
inflammation might play a considerable role in the development of synovial fibrosis.  
1.4 Synovial fibrosis in advanced OA 
Major abnormalities observed in the OA synovium include synovial hyperplasia, inflammatory 
cell infiltration, angiogenesis and fibrosis [11]. Fibrosis is a non-physiological wound healing 
process that is characterized by excessive deposition of ECM proteins, in particular collagens 
coupled with reduced turnover [42] . Synovial fibrosis is a common feature in advanced OA that 
contributes to joint pain and stiffness [42]. Synovial fibrosis is a prevalent outcome of total knee 
arthroplasty (TKA) where the collagen-rich dense fibrous tissue limits the normal range of motion 
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and contributes to functional deficits [43]. Patients with synovial fibrosis are more likely to 
experience a first and follow-up TKA and reducing the rate of fibrosis may reduce the likelihood 
of a revision TKA [44]. The underlying mechanism that causes synovial fibrosis has not been 
investigated.   
 The TGF-b signaling pathways play an essential role in maintaining joint homeostasis in healthy 
joints, and a switch to a pathologic role that drives synovial fibrosis [45]. Blaney et al showed that 
intra-articular injection of adenovirus overexpressing active TGF-β in the knee joints resulted in a 
significant increase of synovial thickness 2 weeks after injection [46]. Additionally, previous 
observations showed that TGF-b upregulates the expression of synovial collagen type 1, tissue 
inhibitor of metalloproteinase 1 (TIMP-1), and procollagen-lysine, 2-oxoglutarate 5-dioxygenase 
2 (PLOD2) and promotes the differentiation of OA synovial fibroblasts into a myofibroblast-like 
phenotype [47].  Myofibroblasts have enhanced ability to express alpha smooth muscle actin (α-
SMA) and produce collagen, proliferate and migrate [47, 48]. 
Synovial macrophages play an important role in driving OA pathogenesis due to their significantly 
higher production of inflammatory and catabolic mediators, resulting in cartilage degeneration, 
synovial thickening, and osteophyte formation [19]. In addition, local depletion of synovial 
macrophages was shown to mitigate cartilage damage and osteophyte formation in experimental 
OA models [49]. Using a macrophage Fas-induced apoptosis (MaFIA) transgenic mouse, 
clodronate liposomes-mediated depletion of synovial lining macrophages was shown to limit 
cartilage damage and synovial inflammation [49]. In addition to synovial tissue macrophages, 
infiltrating monocytes/macrophages may contribute to OA pathogenesis [18]. Monocytes and 
macrophages are found with increased numbers in arthrofibrotic tissues, which may signal their 
 
 8 
involvement in the pathogenesis of synovial fibrosis [50]. Furthermore, chemotactic factors e.g. 
IL-8 and MCP-1 were highly expressed in fibrotic synovial tissues, infrapatellar fat pad, and SF 
from patients with revision TKA compared to patients with non-fibrotic primary TKA [43, 50, 51].  
Moreover, inflammatory microenvironment in OA synovium has been implicated in switching 
both synovial-resident and infiltrating monocytes/macrophages into two main subsets M1 (pro-
inflammatory) to M2 (anti-inflammatory) [52]. Following tissue injury, monocytes migrate and 
differentiate into M1 inflammatory macrophages [53]. Activation of M1 macrophages is achieved 
by inflammatory cytokines e.g. IFN-g and via the toll-like receptor system [52, 54].  M1 
macrophages produce TGF-β as a regulatory feedback signal to aid in the resolution of 
inflammation [54, 55].  One of the first steps following tissue injury is fibroblasts migration, 
differentiation into myofibroblasts and production of matrix proteins in response to TGF-β [55, 
56]. M2 macrophages are anti-inflammatory by virtue of producing IL-10 and TGF-b, and in this 
regard antagonize the profibrotic role of M1 macrophages [57]. Excessive M2 macrophage 
responses can contribute to pathologic fibrosis via increased production of profibrotic mediators 
e.g. TGF-β [57, 58]. Our understanding of the contribution of M1 and M2 macrophages to OA 
synovitis and synovial fibrosis remains limited.  Available evidence supports that synovial 
macrophage M1 polarization exacerbated synovitis and resolution of synovial inflammation was 
associated with the population of the synovium by M2 macrophages that possess a homeostatic 
anti-inflammatory phenotype [59, 60].  Furthermore, analysis of aspirates collected from patients 
with advanced OA shows that the concentrations of CD163 and CD14, M2 macrophage soluble 
markers, were higher in synovial fluid and plasma in these patients [61]. These data suggest that 
monocytes/macrophages may play a role in regulating synovitis and ensuing synovial fibrosis.  
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1.5 Cyclic adenosine monophosphate 
Cyclic adenosine monophosphate is a pleiotropic intracellular second messenger generated by 
adenylyl cyclase enzymes in response to G-protein coupled receptor (GPCR) activation [62]. The 
antifibrotic effect of cAMP has been shown in fibroblasts from multiple origins and includes 
inhibition of fibroblast proliferation, fibroblast-myofibroblast transition, reduction in fibroblast 
migration and synthesis of ECM components [63, 64]. It has been shown that isoproterenol, a 
cAMP-elevating agent, inhibited TGF-β-stimulated collagen synthesis and α-SMA expression in 
cardiac fibroblasts [63]. Also, stimulation of cAMP production blunted TGF-β-induced pulmonary 
fibroblasts proliferation [64]. The increase in cAMP results in activation of protein kinase A 
(PKA)-dependent and -independent pathways [65, 66]. In the presence of growth factors, cAMP 
elevation activates cAMP-dependent PKA, which interferes with Raf-1 activation and signaling to 
blunt cell proliferation [67]. PKA also activates CREB, which can compete for cofactors with 
SMAD- mediated transcription stimulated by TGF-β1 [63]. In the absence of growth factors, PKA-
dependent and independent pathways stimulate cAMP-mediated cell proliferation [68].  However, 
the role of cAMP in controlling TGF-b fibrotic response in osteoarthritic synovial fibroblasts 
remains unknown. 
1.6 Homeostatic roles of proteoglycan-4 (PRG4) and hyaluronan in the articular joint 
Lubricin/Proteoglycan 4 (PRG4) is a glycoprotein secreted from synovial fibroblasts and 
superficial zone chondrocytes and has a multifaceted function including boundary lubrication, 
friction lowering of apposed cartilage surfaces and prevention of synovial overgrowth [69-72].  
PRG4 is abundant in synovial fluid (SF) and PRG4 SF levels are reduced following acute joint 
trauma and in patients with osteoarthritis and rheumatoid arthritis (RA) [73, 74].  In animal models 
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of posttraumatic osteoarthritis (PTOA) and inflammatory arthritis, Prg4 expression is reduced in 
cartilage and synovium [75-77].  Cartilage biosynthesis of PRG4 is reduced as a result of IL-1β 
and TNFα exposure but is increased with TGFβ [78, 79].  In synoviocytes, Prg4 expression is 
reduced by IL-1β and is increased by TGFβ and TGFβ-linked PRG4 accumulation is 
counterbalanced by IL-1β [79, 80].  Loss of function mutations in the Prg4 gene is evident in the 
autosomal recessive disease Camptodactylyl-Arthropathy-Coxa Vara Pericarditis (CACP) 
syndrome which is a juvenile-onset arthropathy [81].  This phenotype is recapitulated in the Prg4 
knockout (Prg4-/-) mouse, which displays progressive synovial hyperplasia, cartilage surface 
fibrillations and damage [81].  PRG4’s joint homeostatic role is further evidenced by the ability of 
purified human PRG4, recombinant full-length or truncated PRG4 to retard cartilage degeneration, 
enhance cartilage repair and reduce chondrocyte apoptosis in PTOA models [82].  PRG4’s protein 
core is 1,404 amino acids long with globular N and C termini and a central mucin domain (Fig. 
1.5).  The central mucin domain is heavily glycosylated via O-linked β 1-3)Gal-GalNAc 
oligosaccharides, and is configured to form a nanofilm that exerts repulsive forces, and provides 
the basis for its anti-adhesive and lubricating properties [83].  Removal of the saccharides from 
PRG4 results in a loss of boundary lubricating ability, while the C-terminus may facilitate surface 
binding of the protein [83].  The specific pattern of glycosylation may play a role in mediating 
PRG4’s biological functions [84].  PRG4 from RA SF exhibits increased siyalylation potentially 
leading to an altered glycosylation-dependent biological role for PRG4 [85].  PRG4 is shown to 
bind to L-selectin in a glycosylation-dependent manner and coats polymorphonuclear granulocytes 
recruited to inflamed synovia and SF of patients with RA [84, 85].  PRG4 was shown to bind the 
CD44 receptor in a concentration-dependent manner and competes with high-molecular weight 
hyaluronan, a CD44 ligand, on binding to CD44 [86].  rhPRG4-CD44 interaction mediates 
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rhPRG4’s ability to inhibit IL-1β and TNFα-induced proliferation of fibroblast-like synoviocytes 
from patients with RA. The downstream effect of engaging the CD44 receptor by rhPRG4 is 
blocking NF-κB nuclear translocation [86]. Also PRG4 was shown to bind TLR2 and TLR4 
receptors and acts as an antagonist to prevent TLR2 and TLR4 activation by bacterial ligands [40].   
HA, a major ECM glycosaminoglycan, is a high molecular-weight polysaccharide [87]. HA is 
produced by fibroblast-like synoviocytes and synthesized as high–molecular weight (HMW) forms 
(MW, >1000 kDa) by HA synthase (HAS) with three isoforms identified to date (HAS1, HAS2, 
and HAS3) [88]. HA is a primary lubricant molecule in synovial fluid with concentration ranges 
1 to 4 mg/mL [87]. HA mediates its biological functions through binding to transmembrane 
receptor, CD44 [89]. Recent studies showed that high molecular weight hyaluronic acid (HMW-
HA) suppressed IL-1β –mediated NF-κB activation and downstream expression of MMP-1 and 
MMP-3 in OA synovial cells in a CD44-dependent manner [90]. Additionally, HA’s anti-
inflammatory effects may be mediated by its ability to modulate TLR2 and TLR4 cartilage 
expression in experimental arthritis [91]. In addition, HA play an important role in joints fibrosis, 
as intraarticular injection of HA reduced TGF-b1-induced synovial fibrosis in a murine model of 
OA [92].  
1.7 Cluster determinant 44 (CD44) receptor and associated signaling pathways 
CD44 is a transmembrane glycoprotein, with various isoforms generated by alternative splicing, 
plays a crucial role in cell adhesion, development, endocytosis, tissues homeostasis, and in a 
variety of inflammatory diseases [93]. CD44 has an established role in hyaluronan metabolism and 
cellular uptake [89, 93]. CD44 was shown to bind to osteopontin, collagen, and MMPs and 
different ECM components including PRG4, HA [94]. 
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Previous studies have suggested that CD44 has role in OA development. CD44 expression was 
detected in synovia and cartilage of patients with different severities of OA [95]. CD44 receptor 
has a role in regulating cell signaling pathways.  A study by Rothman et al demonstrated that anti-
CD44 mAb elevates cAMP and inhibits the increase in intracellular Ca2+ in human T lymphocytes 
[96]. It was suggested that CD44 might be positively coupled with adenylyl cyclase and that 
activation of adenylyl cyclase by anti-CD44 mAb or forskolin, an adenylyl cyclase activator, may 
inhibit the increase in intracellular Ca2+ in human T lymphocytes [96]. In the context of innate 
immunity, CD44 was found to regulate Fcγ and complement receptor 3-dependent macrophage 
phagocytosis [93, 97]. Additionally, CD44 may play a role in the negative regulation of TLR 
receptor activation [98]. Furthermore, CD44 engagement by the antibody resulted in PP2A activity 
activation and inhibition of PP2A activity revered the anti-inflammatory effect of the antibody 
[99]. In addition to its role in mediating cellular migration and inflammation, CD44 receptor 
contributes to fibrosis in response to injury.  CD44+/+ fibroblasts produce more active TGF-b1 than 
CD44-/- fibroblasts [100], suggesting an effect of CD44 targeting in suppressing the activation of 
fibroblasts. 
1.8 Significance  
OA fibrosis is a common outcome of advanced OA that contributes to joint pain, stiffness and 
functional deficits.  OA fibrosis is an immune mediated disease characterized by fibroblast cell 
migration, proliferation and transition to a myofibroblast phenotype characterized by alpha smooth 
muscle actin (a-SMA) upregulation and stress fiber formation. Synoviocytes produce 
proteoglycan-4 (PRG4; lubricin), a heavily glycosylated mucinous glycoprotein, and hyaluronic 
acid (HA).  PRG4 is abundant in synovial fluid (SF) and PRG4 SF levels are reduced following 
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acute joint trauma and in patients with OA.  PRG4 play an important role in joint lubrication and 
it binds to CD44, the HA receptor, to exert an anti-inflammatory effect in the articular joint.  The 
role of synovial PRG4 in the context of resolution of synovitis and development of fibrosis remains 
unknown.  Moreover, the pathological mechanisms that cause OA fibrosis are unclear, and current 
treatments include physical therapy and revision surgeries. Given that OA fibrosis develops in ~3-
10% of patients with total knee arthroplasty (TKA), there is a significant need for new prophylactic 
and/or treatment modalities.  This study expands our understanding of the pathophysiology of OA 
fibrosis and provides us with the rationale to pursue PRG4 as a promising biologic treatment to 
prevent and/or treat OA fibrosis.  
1.9 Hypothesis 
PRG4 in synovial fluid possesses an anti-inflammatory and antifibrotic effect that prevents 
immune-mediated TGF-b activation and OA fibrosis is associated with a reduction in PRG4’s 
biological effect. 
1.10 Specific Aims: 
We propose three interconnected aims to test our overall hypothesis: 
Aim 1: To evaluate the role of CD44 in regulating NF-kB activation and proinflammatory cytokine 
production in response to TLR2 receptor activation in human macrophages using a combination 
of CD44 receptor knockdown, TNF-α production by macrophages from CD44 wildtype and 
knockout mice, and CD44 receptor engagement by CD44-neutralizing antibody and HA 
treatments.  
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Hypothesis:  
CD44 regulates TLR2 activation of human macrophages, whereby a reduction in CD44 levels or 
engagement of CD44 by its ligand (HA) or CD44-specific antibody reduces downstream pro-
inflammatory cytokine production.  
Aim 2: To investigate the antifibrotic function of cAMP, generated by forskolin treatment, in TGF-
β stimulated OA synoviocytes and study the contribution of synovial fluid components PRG4 and 
HA to OA fibrosis.  
Hypothesis: Increasing intracellular cAMP exerts an antifibrotic effect in OA synovial fibroblasts 
and promotes PRG4 and HA secretion.  
 
Aim 3: To examine the role of PRG4-CD44 interaction in regulating synovial tissue fibrosis in 
vitro and in vivo. 
 Hypothesis: PRG4 regulates fibroblast to myofibroblast transition and modulates fibroblast 
migration in response to exogenous TGF-b or co-incubation with lipopolysaccharide (LPS) 
stimulated macrophages in a CD44-dependent manner.  
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1.11 Figures 
 
Figure 1.1 Involvement of the synovium in OA pathophysiology. Products of cartilage 
breakdown that are released into the synovial fluid are phagocytosed by synovial cells, 
amplifying synovial inflammation [12]. 
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Figure 1.2 The role of proinflammatory cytokines in the pathophysiology of osteoarthritis (OA). 
The levels of proinflammatory cytokines, including IL-1β, TNF and IL-6, are elevated in OA [10] 
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Figure 1.3 Canonical and non-canonical TGF-β signaling pathways. (A) In the canonical signaling 
pathway, biologically active TGF-β ligands bind to TGFβRII, which in turn activates TGFβRI. 
TGFβRI-regulated SMAD2/3 proteins are phosphorylated at their C-terminal serine residues and 
form complexes with SMAD4 (co-SMAD), initiating a number of biological processes through 
transcriptional regulation of target genes. (B) In the non-canonical signaling pathways, the TGF-β 
receptor complex transmits its signal through other factors, such as the mitogen-activated protein 
kinases (MAPKs), phosphatidylinositide 3-kinase (PI3K), and TNF receptor-associated factor 4/6 
(TRAF4/6). Activated MAPKs can exert transcriptional regulation either through direct interaction 
with the nuclear SMAD protein complex or via other downstream proteins. Moreover, TGF-β 
activation of the TRAF proteins can initiate nuclear factor-κB (NF-κB) signaling activity, leading 
to the inflammatory response among other processes [101].  
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Figure 1.4 Toll-like receptor signaling pathway. Toll-like receptors (TLRs; with the exception of 
TLR3) induce nuclear factor-κ B (NF- κ B) dependent cytokine production through a pathway 
involving the adaptor molecule myeloid differentiation primary-response gene 88 (MyD88). 
However, TLR3 (and TLR4) transduce signals through a MyD88-independent signaling pathway 
that involves the adaptor molecule Toll/IL-1 receptor domain-containing adaptor inducing IFN- β 
(TRIF) [102].  
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Figure 1.5 Schematic depicting the various motifs within the 1,404 amino acid proteoglycan-
4 (PRG4) polypeptide. 
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Abstract 
Osteoarthritis (OA) is a low-grade chronic inflammatory joint disease.  Innate immunity 
contributes to OA progression, mediated by toll-like receptors (TLR2 and TLR4).  We evaluated 
the role of CD44, a transmembrane glycoprotein, in regulating TLR2-linked macrophage 
activation and resultant proinflammatory responses.  TLR2 stimulation was performed on 
differentiated THP-1 macrophages in the presence or absence of a CD44-specific antibody or 
hyaluronan (HA).    Nuclear factor kappa B (NFkB) nuclear translocation; interleukin-1 beta (IL-
1b) and tumor necrosis factor alpha (TNF-a) gene expression and protein concentrations were 
determined.  Anti-CD44 antibody and HA treatments reduced NFkB translocation, IL-1b and 
TNF-a expression and production (p<0.001).  Inhibition of proinflammatory response in 
macrophages by HA was mediated by CD44.  Protein phosphatase 2A (PP2A) mediated the 
reduction in NFkB translocation by HA.  CD44 Knockdown reduced NFkB nuclear translocation 
and downstream IL-1b and TNF-a protein production following TLR2 receptor stimulation 
(p<0.001).  CD44+/+ murine bone marrow derived macrophages (BMDMs) produced higher TNF-
a compared to CD44-/- macrophages following TLR2 stimulation (p<0.01).  HA dose-dependently 
inhibited TLR2 induced TNF-a production by murine BMDMs (p<0.001).  OA synovial fluids 
(SF) stimulated TLR2 and TLR4 receptors and induced NFkB translocation in THP-1 
macrophages.  Anti-CD44 antibody treatment significantly reduced macrophage activation by OA 
SF (p<0.01).  CD44 regulated TLR2 responses in human macrophages, whereby a reduction in 
CD44 levels or engagement of CD44 by its ligand (HA) or a CD44-specific antibody reduced 
NFkB translocation and downstream proinflammatory cytokine production.  A CD44-specific 
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antibody reduced macrophage activation by OA synovial fluids and CD44 is a potentially novel 
target in OA treatment.   
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2.1 Introduction  
Osteoarthritis (OA) is a degenerative joint disease involving joint structures e.g. the articular 
cartilage, synovium and subchondral bone [103, 104].   Risk factors for OA pathogenesis include 
age, obesity, traumatic joint injury, and low-grade chronic inflammation [103, 105-109].  
Inflammation of the synovial tissue is recognized as an active contributor to OA pathogenesis with 
multiple studies showing a correlation between the extent of synovitis and pain, cartilage erosion 
and disease progression [110-114].  The synovium is a soft tissue that is comprised of a surface 
layer, the intima and an underlying subintima [112, 115].   The intima of normal synovium is 1-3 
cell layers thick, with two cell types: fibroblast-like synoviocytes and macrophages [115, 116].  
Chronically inflamed synovium, as seen in OA, is characterized by synovial intimal hyperplasia, 
immune cell infiltration, subintimal fibrosis and neovascularization [117, 118].      
Infiltrating immune cells detected most frequently in OA synovial tissues include macrophages, T 
cells and to a lesser extent mast cells and B cells [117, 119, 120].  Synovial macrophages play an 
important role in driving OA pathogenesis due to their significantly higher production of 
proinflammatory cytokines e.g. interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-
α) compared to fibroblast-like synoviocytes [121, 122].  Activation of synovial macrophages was 
shown to promote synovial thickening, osteophyte formation and cartilage degeneration in 
experimental OA models [123, 124].  As a component of the innate immune system, macrophages 
can be activated by damage-associated molecular patterns (DAMPs) through interaction with 
pattern recognition receptors, e.g. toll-like receptors (TLRs) on the surface of macrophages [125].  
Examples of DAMPs in OA include extracellular matrix breakdown products e.g. biglycan, 
fibronectin fragments, low molecular weight hyaluronic acid, plasma proteins e.g. α1 and α2 
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macroglobulins, intracellular alarmins e.g. high mobility group box 1 (HMGB1) and crystals e.g. 
uric acid [126]. 
Hyaluronan (HA) is produced by fibroblast-like synoviocytes and is a major component of the 
synovial fluid.  HA exerts important functions in the joint and its biological effects are mediated 
by its binding to its transmembrane receptor, cluster determinant 44 (CD44) [127].  In OA 
synoviocytes, HA suppresses IL-1β mediated nuclear factor kappa B (NFκB) activation and 
downstream expression of matrix metalloproteinases (MMPs) in a CD44-dependent manner [128, 
129].  Additionally, HA’s anti-inflammatory effects may be mediated by its ability to modulate 
TLR2 and TLR4 cartilage expression in experimental arthritis [130]. 
In this work, we aimed to evaluate the role of CD44 in regulating NFκB activation and 
proinflammatory cytokine production in response to TLR2 receptor activation in human 
macrophages, using a combination of CD44 receptor knockdown, TNF-α production by 
macrophages from CD44 wildtype and knockout mice, and CD44 receptor engagement by CD44 
neutralizing antibody and HA treatments.  We hypothesized that CD44 functions to regulate NFκB 
activation and downstream IL-1β and TNF-α gene expression and production in response to TLR2 
stimulation of a human macrophage cell line.  Finally, we studied TLR2 and TLR4 receptor 
activation by OA synovial fluids and examined the effect of CD44 targeting in suppressing the 
activation of macrophages by these fluids. 
2.2 Materials and Methods 
2.2.1 Differentiation of THP-1 monocytes into macrophages 
THP-1 monocytes were obtained from American Type Culture Collection (ATCC, USA).  Cells 
were cultured to a density of 1.5 x 106 cells/mL in 75 cm flask in RPMI 1640 medium 
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supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10mM HEPES, 2mM 
glutamine, 100U/L penicillin and 100µg/mL streptomycin and maintained at 37oC under 5% CO2.  
In sterile 12 well plates (Corning, Sigma Aldrich, USA), 600,000 cells in 2 ml RPMI 1640 media 
were differentiated into macrophages by incubation with phorbol 12-myristate-13-acetate (PMA; 
Sigma Aldrich) to a final concentration of 5 ng/ml for 48 hours [131].  Subsequently, media 
supernatants were removed and wells were washed three times with sterile PBS to remove 
unattached cells and new RPMI 1640 media was added.   
2.2.2 CD44, TLR2 and TLR4 expression in THP-1 macrophages 
THP-1 macrophages were incubated with CD44-specific, TLR2-specific or TLR4-specific 
antibody (Abcam, USA) at a final concentration of 1µg per 600,000 cells for 1 hour at 4oC.  Cells 
were subsequently pelleted and the cell pellet was washed three times with PBS.  THP-1 cells were 
subsequently incubated with DyLight® 488 goat anti-mouse IgG (Abcam) at 1:500 dilution for 30 
min at 4oC.  Following cell pelleting and washing, 500 μL of 4% paraformaldehyde was added and 
cell-associated fluorescence was determined by flow cytometry using BD FACSVerse (BD 
Biosciences, USA). 
2.2.3 Impact of TLR2 and TLR4 receptor activation on IL-1b and TNF-a production by 
THP-1 macrophages 
THP-1 macrophages (600,000 cells per well) were treated with Pam3CSK4 (Pam; Invivogen, 
USA), a TLR2 ligand [132], at a concentration range between 0.1 and 10 ng/ml for 24 hours.  
Similarly, THP-1 macrophages (600,000 cells per well) were treated with lipopolysaccharide 
(LPS; Invivogen, USA), a TLR4 ligand, at a concentration range between 0.1 and 10 ng/ml for 24 
hours.  Media supernatants were collected and IL-1b and TNF-a concentrations were determined 
using commercially available ELISA kits (R&D systems, USA).   
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2.2.4 HA binding to recombinant human CD44 and TLR2 receptors   
High-binding microtiter plates (Corning, Sigma Aldrich) were used to coat recombinant human 
CD44 Fc chimeric protein or recombinant human TLR2 (R&D systems) overnight at 4oC.  Each 
well received 100μL of CD44 or TLR2 protein (1 ng/ml each) in PBS.  Wells that were coated 
with CD44 or TLR2 were blocked with 2% bovine serum albumin (BSA; 300μL per well) for 2 
hours at room temperature.  Biotinylated HA (MW 1,500 kDa, Creative PEGWorks, USA) was 
added to the plate in serial dilutions and incubated for 1 hour at room temperature.  Following 
washing with PBS+0.1% Tween 20, streptavidin-HRP (R&D systems) was added at 1:10,000 
dilution and incubated for 1 hour at room temperature.  Following washing with PBS+0.1% tween 
20, the assay was developed using 1-step Turbo TMB ELISA reagent (Lifetechnologies, USA) 
and the absorbance was measured at 450 nm.  Data is presented as percent maximal binding.  Data 
represents the mean ± standard deviation (S.D.) of three independent experiments with duplicate 
wells per group.   
2.2.5 Impact of HA and CD44-specific antibody treatments on TLR2 ligand induced nuclear 
factor kappa B (NFκB) nuclear translocation in THP-1 monocytes and macrophages          
THP1-XBlue cells (Invivogen, USA) is a THP-1 monocyte cell line that stably expresses AP-1 
and NFκB inducible secreted embryonic alkaline phosphatase (SEAP) reporter gene.  Upon 
activation of TLR2, SEAP is secreted and its activity can be monitored using an alkaline 
phosphatase substrate [133].  THP1-XBlue cells were cultured in RPMI 1640 media supplemented 
with 4.5 g/L glucose, 10% FBS, 50 U/mL penicillin, 50 μg/mL streptomycin, 100 μg/mL normocin 
and 2 mM L-glutamine. 
THP1-XBlue cells (50,000 cells per well in HEK detection media) (100 μL per well) were treated 
with Pam (5 ng/ml) in the absence or presence of HA (MW >950 kDa; R&D systems) at a final 
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concentration of 250 and 500 μg/ml, an anti-CD44 antibody (2.5 μg/ml; Abcam) or an isotype 
control antibody (2.5 μg/ml; Abcam) for 24 hours followed by measuring the 630 nm absorbance.   
THP-1 macrophages (600,000 cells per well) were treated with Pam (5 ng/ml) in the absence or 
presence of HA (100, 250 and 500 μg/ml) for 1 hour followed by cell harvesting and nuclear 
protein extraction using a commercially available kit (Thermo Fisher Scientific, USA).  Protein 
content in the nuclear extract was quantified in all experimental groups and a total of 3 μg of total 
protein was used to quantify NFκB p65 subunit nuclear levels using a DNA binding ELISA assay 
(Abcam).  In another set of experiments, THP-1 macrophages were pre-treated with okadaic acid 
(5nM; Tocris Biosciences, USA), a potent inhibitor of protein phosphatase 2A, for 2 hours 
followed by treatment with Pam (5ng/ml) in the absence or presence of HA (250 μg/ml) for 1 hour 
followed by nuclear NFκB p65 subunit quantification as described above.  Data is presented as 
detectable nuclear p65 levels normalized to control.  Data represents the mean ± S.D. of three 
independent experiments with duplicate wells per treatment. 
2.2.6 Impact of HA and CD44-specific antibody treatments on TLR2 ligand induced IL-1β 
and TNF-α gene expression and production in THP-1 macrophages 
THP-1 macrophages (600,000 cells per well) were treated with Pam (1 ng/ml) in the absence or 
presence of HA (100, 500 and 1,000 μg/ml) for 6 hours followed by RNA extraction using TRIzol 
reagent (Thermo Fisher Scientific) and RNA concentrations were determined using a NanoDrop 
ND-2000 spectrophotometer (NanoDrop Technologies, USA).  cDNA was synthesized using 
Transcriptor First Strand cDNA Synthesis Kit (Roche, USA).  Quantitative PCR (qPCR) was 
performed on Applied Biosystems StepOnePlus Real-Time PCR System (Thermo Fisher 
Scientific) using TaqMan Fast Advanced Master Mix (Life Technologies). The cycle threshold 
(Ct) value of IL-1β (Hs00174097_m1; Thermo Fisher Scientific) was normalized to the Ct value 
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of GAPDH (Hs02758991_g1; Thermo Fisher Scientific) in the same sample, and the relative 
expression was calculated using the 2-ΔΔCt method [134].  Data is presented as fold target gene 
expression compared to untreated control.  
In another set of experiments, THP-1 macrophages (600,000 cells per well) were treated with Pam 
(5ng/ml) in the absence or presence of HA (100, 500 and 1,000 μg/ml), anti-CD44 antibody (2.5 
μg/ml) or isotype control antibody (2.5 μg/ml) for 24 hours.  IL-1β and TNF-α media 
concentrations were determined using commercially available ELISA kits.   
2.2.7 Impact of HA treatment on TLR2 ligand induced CD44 expression in THP-1 
macrophages 
THP-1 macrophages (600,000 cells per well) were treated with Pam (5 ng/ml) in the absence or 
presence of HA (100, 500 and 1,000 μg/ml) for 6 hours followed by RNA isolation, cDNA 
synthesis and qPCR as described above.  The Ct value of CD44 (Hs01075864_m1; Thermo Fisher 
Scientific) was normalized to the Ct value of GAPDH in the same sample, and the relative 
expression was determined as described above.  Data is presented as fold CD44 expression 
compared to untreated control.  
In another set of experiments, THP-1 macrophages were treated as described above for 24 hours 
followed by cell harvest.  THP-1 macrophages were incubated with anti-CD44 antibody (1µg per 
600,000 cells) for 1 hour at 4oC.  Cells were subsequently pelleted and the cell pellet was washed 
three times with PBS.  THP-1 cells were subsequently incubated with DyLight® 488 goat anti-
mouse IgG at 1:500 dilution for 30 min at 4oC.  Following cell pelleting and washing, cell-
associated fluorescence was determined as described above.  
 
 29 
2.2.8 CD44 receptor knockdown and associated TLR2 ligand induced IL-1β and TNF-α 
production in THP-1 macrophages and role of HA 
THP-1 macrophages (600,000 cells per well) were treated with a pre-validated CD44 small 
interfering RNA (siRNA) (Thermo Fisher Scientific) (25 pmoles per well) or a non-targeted 
negative control (NC) siRNA (25pmoles) (Thermo Fisher Scientific) for 48 hours.   Transfection 
was performed using Lipofectamine RNAiMax (Thermo Fisher Scientific) per manufacturer’s 
recommendations.  To confirm CD44 knockdown, CD44 gene expression was determined in CD44 
siRNA and NC siRNA-treated THP-1 macrophages as described above and compared to CD44 
expression in untreated control macrophages.  Additionally, CD44 and TLR2 protein levels in 
CD44 siRNA, NC siRNA-treated and untreated control THP-1 macrophages were determined 
using flow cytometry as described above. 
NFκB p65 subunit nuclear levels in CD44 siRNA, NC siRNA-treated and untreated control THP-
1 macrophages (600,000 cells per well) following treatment with Pam (5ng/ml) for 1 hour were 
determined as described above.    CD44 siRNA, NC siRNA-treated and untreated control THP-1 
macrophages (600,000 cells per well) were treated with Pam (5ng/ml) for 24 hours.  In another set 
of experiments, Pam treatment was performed in the absence or presence of HA (500 μg/mL).  IL-
1β and TNF-α media concentrations were determined as described above.   
2.2.9 TLR2 ligand induced TNF-α production in murine bone marrow derived macrophages 
from CD44+/+ and CD44-/- mice and effect of HA treatment on primary murine macrophages  
CD44-/- (JAX stock # 005085) and CD44+/+ (JAX stock # 00664) pathogen-free male mice (n=8 
in each group) were acquired from the Jackson Laboratory (Maine, USA) [135].  Animals (10-14 
weeks old) were euthanized and isolation and culture of bone marrow derived macrophages 
(BMDMs) was performed as previously described [136].  Both femurs and tibia bones were 
carefully dissected and bone marrows were flushed using a sterile 25G needle filled with 
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DMEM/F12 medium (Fisher Scientific) supplemented with 10ng/ml macrophage colony-
stimulating factor (M-CSF; R&D systems).  Cells were subsequently cultured for 7 days with 
media change on day 3.  On day 7, BMDMs were gently scraped and dislodged using Corning 
Cellstripper Solution (VWR, USA) for 5 min at 37oC.  An equal volume of macrophage complete 
medium was added to the cells and the cells were centrifuged for 10 min at 400 x g and 4oC, and 
the supernatant was discarded.  Subsequently, BMDMs were plated to perform TLR2 stimulation 
studies or to characterize surface markers Cd11b and F4/80 expression using flow cytometry.   
BMDMs (400,000 cells) were treated with FITC-labeled anti-CD11b antibody (abcam) (1:500 
dilution), PE-Texas Red-labeled anti- F4/80 antibody (ThermoFisher Scientific) (1:500 dilution) 
or FITC-labeled Rat IgG2b, kappa monoclonal - Isotype control (Abcam) for 1 hr at 370C.  Cells 
were subsequently pelleted and the cell pellet was washed three times with PBS. Following cell 
pelleting and washing, 500 μL of 4% paraformaldehyde were added and cell-associated 
fluorescence was determined by flow cytometry. 
BMDMs from both genotypes were plated overnight in 12 well plates (200,000 cells per well).  
Cells were treated with Pam (1 ng/ml or 5 ng/ml) for 6 hours at 37oC and TNF-α media 
concentrations were determined using a commercially available ELISA (R&D Systems).  In 
another set of experiments, CD44+/+ BMDMs were treated with Pam (5 ng/ml) in the absence or 
presence of HA (100, 250 and 500 μg/ml) for 6 hours at 37oC and TNF-α media concentrations 
were determined as above.  Data is presented as the mean TNF-α concentrations ± S.D. of 4 
independent experiments, with triplicate wells per treatment.  All animal tissue harvests were 
approved by the IACUC committee at Chapman University.  
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2.2.10 Activation of TLR2 and TLR4 receptors by synovial fluids from patients with OA and 
the role of CD44 in regulating macrophage activation in response to OA synovial fluids 
Synovial fluid aspirates (SF) were collected from patients with OA (n=12) (Articular Engineering, 
USA) following knee replacement surgery or from donors within 24 hours of death, collected with 
partner site IRB approval with informed written consent from the donor or nearest relative.  A total 
of 6 patients were female.   The median age (interquartile range) of the group was 71 (60 to 82).   
Normal SF specimens (n=4) were obtained from subjects with no clinical history of joint disease 
or arthritis, and were provided by Dr. Martin Lotz from the Scripps Research Institute, USA.  
Screening of OA SF specimens for activation of TLR2 and TLR4 receptors was performed by 
incubation with TLR2-HEK and TLR4-HEK cells (25,000 cells per well in HEK Blue detection 
media) (Invivogen).  The volume of SF aspirates was 7.5μL per well, corresponding to 3.75% 
dilution.   The final volume in each well was 200μL.  Activation of TLR2 or TLR4 in these cells 
results in nuclear translocation of NFκB and expression of SEAP, whose activity can be detected 
in the culture media.  Cells were incubated with the SF samples for 48 hours at 37oC.  The 630 nm 
absorbance was measured and normalized to the 630 nm absorbance values of untreated control 
cells. 
THP1-XBlue monocytes (25,000 cells per well) were maintained in serum-free RPMI 1640 for 48 
hours followed by differentiation of the THP-1 monocytes into macrophages as described above.  
SF aspirates with detectable TLR2 and TLR 4 activity were incubated with THP1-XBlue 
macrophages for 48 hours in HEK Blue detection media in the absence or presence a CD44-
specific antibody (2.5μg/ml), TLR2-specific antibody (Abcam; 2.5 μg/ml) or isotype control (2.5 
μg/ml).  Normal SF specimens were used as controls.   The 630 nm absorbance was subsequently 
measured.  Data is presented as the mean 630 nm absorbance value of each SF specimen, based 
on two independent experiments with duplicate wells per experiment. 
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  2.2.11 Statistical Analyses 
Unless otherwise specified, data is presented as the mean ± S.D. of 4 independent experiments 
with at least duplicate wells per group.  Continuous variables were tested for normality and equal 
variances.  Variables that satisfied both assumptions were tested for statistical significance using 
Student’s t-test for two group comparisons.  Multiple group comparisons were performed using 
analysis of variance with Tukey’s post-hoc test.  Variables that did not satisfy the normality 
assumption were tested using Mann-Whitney U test or ANOVA on the ranks.  The level of 
statistical significance was a priori set at α=0.05.   
2.3 Results 
2.3.1 CD44 and TLR receptor expression in human THP-1 macrophages and 
proinflammatory cytokine production 
A representative flow cytometry histogram depicting cell-associated fluorescence of THP-1 
macrophages following probing with CD44, TLR2 or TLR4 antibodies is shown in figure 2.1A.  
Compared to unstained cells, cell associated fluorescence for CD44 and TLR2 exhibited a right 
shift indicating expression of CD44 and TLR2 by THP-1 macrophages.  On the contrary, cell 
associated fluorescence for TLR4 was not qualitatively different from unstained control cells.  
TLR2 receptor activation resulted in a concentration-dependent elevation in media IL-1β (fig. 
2.1B) and TNF-α (fig. 2.1C) concentrations.  Similarly, TLR4 receptor activation resulted in 
detectable IL-1β and TNF-α levels.  Across all ligand treatments, TLR2 activation resulted in a 
significantly higher (p<0.001) IL-1β and TNF-α production compared to TLR4 activation. 
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2.3.2 HA and CD44-specific antibody treatments reduced TLR2 ligand induced NFκB 
nuclear translocation in THP-1 monocytes and macrophages 
HA binding to immobilized TLR2 and CD44 receptors is shown in figure 2.2A.  HA exhibited 
concentration-dependent binding to CD44 with no detectable binding to TLR2.  Pam treatment 
resulted in NFκB nuclear translocation in THP-1 monocytes compared to untreated cells (p<0.001) 
(fig. 2.2B).  HA (250 and 500 μg/mL) treatment reduced NFκB nuclear translocation in THP-1 
monocytes (p<0.01; p<0.001) following TLR2 receptor activation.  Similarly, Anti-CD44 
antibody treatment reduced NFκB nuclear translocation in THP-1 monocytes (p<0.001).  In 
contrast, isotype control antibody treatment did not alter NFκB nuclear translocation.  There was 
no difference in the magnitude of reduction of NFκB nuclear translocation in THP-1 monocytes 
with HA (500 μg/mL) or a CD44 antibody treatments. 
TLR2 receptor activation resulted in NFκB p65 subunit nuclear translocation in THP-1 
macrophages compared to untreated cells (p<0.001) (fig. 2.2C).  HA (250 and 500 μg/mL) 
treatments reduced p65 subunit translocation (p<0.01) in THP-1 macrophages following TLR2 
receptor activation.  Okadaic acid treatment did not alter NFκB p65 subunit translocation following 
TLR2 receptor activation (fig. 2.2D).  NFκB p65 subunit nuclear levels were significantly higher 
in the Pam + HA + Okadiac acid group compared to Pam + HA group (p<0.01).           
2.3.3 HA and CD44-specific antibody treatments reduced TLR2 ligand stimulated 
proinflammatory cytokine expression and production in THP-1 macrophages 
TLR2 activation induced IL-1β gene expression and production in THP-1 macrophages (p<0.001) 
(fig. 2.3A and fig. 2.3C).  HA (500 and 1,000 μg/mL) treatment reduced IL-1β gene expression in 
THP-1 macrophages following TLR2 activation (p<0.05; p<0.01) (fig. 2.3A).  Correspondingly, 
HA (500 and 1,000 μg/mL) treatment reduced IL-1β production by THP-1 macrophages (p<0.001) 
(fig. 2.3C).  TLR2 activation induced TNF-α gene expression and production in THP-1 
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macrophages (p<0.001) (fig. 2.3B and fig. 2.3D).  HA (500 and 1,000 μg/mL) treatment reduced 
TNF-α gene expression in THP-1 macrophages following TLR2 activation (p<0.01) (fig. 2.3B).  
Similarly, HA (500 and 1,000 μg/mL) treatment reduced TNF-α production by THP-1 
macrophages (p<0.001) (fig. 2.3D).  CD44 antibody treatment reduced IL-1β and TNF-α media 
supernatant concentrations following TLR2 activation (p<0.001) (Fig. 2.3E and fig. 2.3F).  In 
contrast, IL-1β and TNF-α media concentrations were not significantly different between Pam 
alone and Pam + isotype control (IC) antibody groups. 
2.3.4 HA reduced CD44 expression following TLR2 receptor activation in THP-1 
macrophages 
TLR2 activation induced CD44 gene expression in THP-1 macrophages (p<0.001) (fig. 2.4A).  
HA (100, 500 and 1,000 μg/mL) treatment reduced CD44 expression in THP-1 macrophages 
following TLR2 activation (p<0.01).  A dose-response for HA treatment was observed as CD44 
expression in the Pam + HA (1,000 μg/mL) group was significantly lower than CD44 gene 
expression in the Pam + HA (500 μg/mL) and Pam + HA (100 μg/mL) (p<0.01; p<0.001).  A 
representative flow cytometry histogram depicting cell-associated fluorescence of THP-1 
macrophages following probing with CD44 antibody is presented in figure 2.4B.  TLR2 activation 
resulted in a right shift of the cell population indicating increased CD44 protein levels on 
macrophages.  HA treatments showed a qualitative reduction in mean cell associated fluorescence, 
indicating a reduction in CD44 receptor levels on macrophages.  Semi-quantitative analysis of 
mean cell-associated fluorescence is shown in figure 2.4C.  Mean fluorescence in the Pam alone 
group was significantly higher compared to untreated control group (p<0.001).  Mean cell-
associated fluorescence in the Pam + HA (1,000 μg/mL) and Pam + HA (500 μg/mL) were 
significantly lower than in the Pam group (p<0.001).  Similarly, mean cell-associated fluorescence 
 
 35 
in the Pam + HA (1,000 μg/mL) and Pam + HA (500 μg/mL) were significantly lower than in the 
Pam + HA (100 μg/mL) group (p<0.01).    
2.3.5 Role of CD44 in regulating downstream responses of TLR2 activation in THP-1 
macrophages 
The impact of CD44 silencing on CD44 gene expression and protein is shown in figures 2.5A and 
2.5B.  CD44 silencing was achieved with approximately 85% reduction in CD44 gene expression 
and 60% reduction in CD44 protein.  CD44 knockdown did not alter TLR2 expression in THP-1 
macrophages (fig. 2.5C).  CD44 knockdown resulted in a significant reduction in NFκB p65 
subunit nuclear levels following TLR2 activation compared to NC siRNA-treated or control THP-
1 macrophages (p<0.001) (fig. 2.5D).   CD44 knockdown resulted in a significant reduction in IL-
1β and TNF-α production following TLR2 activation compared to NC siRNA-treated or control 
THP-1 macrophages (p<0.001) (fig. 2.5E and 2.5F).  There was no significant difference in Pam-
stimulated IL-1β or TNF-α media concentrations between NC siRNA-treated and control THP-1 
macrophages.  HA (500 μg/mL) treatment reduced IL-1β and TNF-α media concentrations 
following TLR2 receptor activation in NC siRNA treated and control THP-1 macrophages 
(p<0.001) (fig. 2.6A and 2.6B).  In contrast, HA (500 μg/mL) treatment did not significantly alter 
IL-1β and TNF-α media concentrations following TLR2 receptor activation in CD44 siRNA-
treated THP-1 macrophages. 
2.3.6 CD44 modulated TLR2 ligand-induced TNF-α production by murine BMDMs and the 
HA treatment suppressed TLR2 ligand activation of primary murine BMDMs. 
TNF-α production by murine BMDMs from CD44-/- and CD44+/+ mice in response to TLR2 
receptor activation and the impact of HA treatment is shown in figure 2.7.  A representative flow 
cytometry scatterplot showing CD11b and F4/80 probing of murine BMDMs is presented in figure 
2.7A.  Murine BMDMs exhibited strong positive staining for both CD11b and F4/80 epitopes, 
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with typically 90% or more of the cell population positive for both surface markers.  Using two-
way ANOVA, we identified a significant interaction between CD44 genotype and Pam 
concentrations (p=0.0035). TNF-α media concentrations in the Pam (1ng/ml and 5 ng/ml) treated 
CD44+/+ BMDMs were significantly higher compared to Pam-treated CD44-/- BMDMs (fig. 2.7B) 
(p<0.001; p<0.01).  The mean TNF-α media concentration in the Pam (1ng/ml) treated CD44-/- 
BMDMs group was approximately 67% lower than corresponding mean TNF-α media 
concentrations in the Pam-treated CD44+/+ BMDMs.  Similarly, the mean TNF-α media 
concentration in the Pam (5ng/ml) treated CD44-/- BMDMs group was approximately 62% lower 
than the corresponding mean TNF-α media concentration in the Pam-treated CD44+/+ BMDMs.  
In CD44+/+ BMDMs, TNF-α concentrations in the Pam (1 and 5ng/ml) groups were significantly 
higher than control group (p<0.001).  Additionally, TNF-α concentration in the Pam (5ng/ml) 
group was significantly higher than the Pam (1ng/ml) group (p<0.001).  In CD44-/- BMDMs, TNF-
α concentrations in the Pam (1ng/ml) group was not significantly different from control CD44-/- 
BMDMs (p=0.1207).  Furthermore, TNF-α concentration in the Pam (5ng/ml) group was 
significantly higher than the Pam (1ng/ml) group (p<0.001).        
The impact of HA treatment on TLR2 ligand induced TNF-α production in CD44+/+ murine 
BMDMs is shown in figure 2.7C.  TNF-α media concentrations in the Pam + HA (100 µg/ml) 
group were not significantly different from TNF-α media concentrations in the Pam alone group.  
TNF-α media concentrations in the Pam + HA (250 µg/ml) group were significantly lower than 
TNF-α media concentrations in the Pam alone and Pam + HA (100 µg/ml) groups (p<0.001).  
Similarly, TNF-α media concentrations in the Pam + HA (250 µg/ml) group were significantly 
lower than TNF-α media concentrations in the Pam alone and Pam + HA (100 µg/ml) groups 
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(p<0.001).  HA (500 µg/ml) alone treatment did not alter TNF-α production compared to untreated 
control cells.        
2.3.7 OA SF specimens activated TLR2 and TLR4 receptors and a CD44-specific antibody 
reduced activation of THP-1 macrophages by OA SF specimens. 
Activation of TLR2 and TLR4 receptors by OA SF specimens is shown in figure 2.8A.  A total of 
8 samples demonstrated significant activation of TLR2 and TLR4 receptors (p<0.001).  In 
contrast, 3 specimens did not exhibit activation of TLR2 or TLR4 and one sample activated TLR2 
receptor but not the TLR4 receptor.  OA SF specimens that activated TLR2 and TLR4 receptors 
also significantly stimulated NFκB nuclear translocation in THP-1 macrophages compared to 
normal SF specimens (p<0.001) (fig. 2.8B).  TLR2 neutralizing antibody treatment significantly 
reduced OA SF activation of THP-1 human macrophages (p<0.01).  Similarly, CD44 antibody 
treatment significantly reduced OA SF activation of THP-1 human macrophages (p<0.01).     
2.4 Discussion 
The TLR family comprises ten functional receptor subtypes with TLR 1-7 and 9 being detected in 
the synovial tissues of patients with OA [107, 118, 137, 138].  A role for TLRs, specifically TLR2 
and TLR4, in the pathogenesis of OA has been suggested [139, 140].  Progressive OA was 
associated with expression of TLR2 in cartilage and chondrocytes derived from a TLR2/TLR4 
double knockout mouse showed attenuated matrix metalloproteinase-13 (MMP-13) expression in 
response to TLR2 stimulation [139, 140].  Furthermore, evidence of macrophage activation in the 
synovial lining was recently reported and the extent of synovial macrophage activation was shown 
to be associated with OA severity and joint pain [141].  In this work, we have examined 
macrophage activation in response to TLR2 and TLR4 activation.  TLR2 and TLR4 ligands 
induced gene expression and production of IL-1b and TNF-a in a concentration-dependent 
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manner.  TLR2 activation produced higher levels of IL-1b and TNF-a compared to TLR4 across 
all ligand concentrations utilized.   This may be due to the relative level of TLR2 and TLR4 
expression on the surface of the macrophages.  Using flow cytometry, we have detected increased 
TLR2 expression compared to TLR4.   This finding is in line with other work that demonstrated 
enhanced TLR2 expression on THP-1 macrophages [142].   TLR2 activation resulted in NFkB 
nuclear translocation in a monocyte NFkB reporter assay.   In macrophages, TLR2 ligands induced 
the nuclear translocation of NFkB p65 subunit.  In addition to the induction of proinflammatory 
cytokines, TLR2 activation significantly increased CD44 gene expression and increased CD44 
protein levels. 
CD44 is a transmembrane receptor, with various isoforms generated by extensive alternative 
splicing and post-translational modifications [143].  In addition to its established role in mediating 
cell adhesion and migration, CD44 receptor has a role in regulating cell signaling pathways, by 
facilitating signaling protein recruitment and assembly [144].  In the context of innate immunity, 
CD44 was found to regulate Fcγ and complement receptor 3-dependent macrophage phagocytosis 
[144].  Additionally, CD44 may play a role in the negative regulation of TLR receptor activation 
[145, 146].  In this present study, a CD44 antibody treatment reduced NFkB nuclear translocation 
and downstream IL-1b and TNF-a gene expression and production.   Additionally, reducing CD44 
expression in human macrophages resulted in a significant attenuation of the latter’s response to 
TLR2 receptor activation and downstream proinflammatory response.   This attenuation is not 
related to the TLR receptor density on the surface of macrophages, as CD44 receptor knockdown 
did not modify TLR2 receptor density on THP-1 macrophages.  The regulatory role of CD44 is 
further highlighted by a strongly attenuated proinflammatory response following TLR2 receptor 
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stimulation of primary macrophages derived from CD44 knockout mice compared to macrophages 
derived from CD44 wildtype animals. 
Protein phosphatase-2A (PP2A) is an abundant intracellular serine/threonine phosphatase with key 
roles in the regulation of many cellular functions including cellular proliferation and immune 
responses [147, 148].  Inhibition of PP2A by okadaic acid resulted in increased nuclear 
translocation of NFκB and AP-1 and IL-1β expression in THP-1 macrophages [147].   
Additionally, CD44 engagement was shown to increase intracellular PP2A [149].  In our work, 
HA suppressed NFκB p65 subunit nuclear translocation in response to TLR2 activation, and that 
effect was shown to be CD44 dependent as HA failed to demonstrate an anti-inflammatory effect 
in response to TLR2 activation in macrophages following CD44 knockdown.  The suppressive 
effect of HA was confirmed in primary murine macrophages as HA treatment dose-dependently 
reduced TNF-a production subsequent to TLR2 receptor stimulation.  Furthermore, the effect of 
HA was mediate by intracellular PP2A activity, as inhibition of PP2A activity reduced the 
inhibitory effect of HA on NFκB activation.  The observed anti-inflammatory activity of HA is 
not due to a direct interaction between HA and the TLR2 receptor as we did not observe any 
significant binding of HA to recombinant TLR2 receptor.  The biological effect of HA in reducing 
TLR2 mediated proinflammatory response in macrophages is physiologically relevant.  The 
concentration of HA in normal SF can vary between 2 and 4 mg/ml [150].  In OA SF aspirates, 
the concentration and molecular weight distribution of HA are significantly reduced, and this 
reduction was associated with TLR2 and TLR4 activation by OA SF aspirates [150, 151].   This 
association may argue for an endogenous homeostatic role for HA in inhibiting synovial 
macrophage activation in response to TLR receptor stimulation by cartilage matrix degradation 
products.  
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A majority of the aspirated SF samples from patients with advanced OA that we examined 
activated TLR2 and TLR4 receptors.   This observation is in agreement with previous reports 
demonstrating activation of TLR2 and TLR4 receptors by OA SF, and augmentation of TLR-
mediated responses in OA fibroblast-like synoviocytes by SF from patients with early stage OA 
[151-153].   Interestingly, SF specimens that activated TLR2 and TLR4 receptors induced NFκB 
nuclear translocation in macrophages, while normal SF specimens treatments failed to activate 
macrophages.   Macrophage TLR2 receptors appeared to mediate NFκB nuclear activation as 
neutralization of TLR2 abrogated macrophage activation by these SF specimens.   CD44 antibody 
treatment produced a similar effect to TLR2 neutralization, providing further support to the utility 
of targeting CD44 to suppress macrophage response to DAMPs present in OA SF. 
We have demonstrated that CD44 receptor plays a significant role in suppressing TLR2-linked 
NFκB nuclear translocation and resultant proinflammatory response in macrophages, in a 
mechanism that involves intracellular PP2A.  Neutralization of the CD44 receptor by its ligand 
hyaluronan, that binds to and is internalized by different cell types including macrophages [127], 
or by a monoclonal antibody resulted in inhibition of NFκB nuclear translocation.  Absence of the 
CD44 receptor or its knockdown produced a similar effect to receptor neutralization by hyaluronan 
or an antibody.  OA SF activated TLR2 and TLR4 receptors and correspondingly induced NFκB 
nuclear translocation in a mechanism that involves TLR2.  Otherwise, a CD44-specific antibody 
reduced macrophage activation by these SF specimens.  In conclusion, CD44 is a potentially novel 
target that may act to limit synovial macrophage activation by cartilage matrix degradation 
products in the joint. 
This study expands the role of CD44 in OA pathogenesis.  CD44 can bind different types of ligands 
and in addition to HA, CD44 was shown to bind proteoglycan-4 (PRG4), a major component of 
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synovial fluids [154].  CD44 expression was shown to be associated with enhanced proliferation 
of synoviocytes from patients with OA, rheumatoid arthritis (RA) as well synoviocytes from Prg4-
/- mice.  Targeting the CD44 receptor by HA or by the recombinant form of PRG4 reduced 
cytokine-induced OA and RA synoviocyte proliferation.  The regulatory role of CD44 in 
controlling downstream effects of IL-1b was further confirmed by the ability of PRG4 to inhibit 
IkB phosphorylation, NFkB nuclear translocation and expression of cartilage degrading enzymes 
by OA synoviocytes in a CD44-dependent mechanism [155].  Our findings are limited by the low 
number of SF aspirates that we have investigated.  Furthermore, we did not ascertain the molecular 
identity of the DAMPs in the SF aspirates that activated TLR receptors and induced NFκB nuclear 
translocation in THP-1 macrophages.  
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2.6 Figures 
 
Fig. 2.1 Toll-like receptors 2 and 4 (TLR2 and TLR4) and CD44 receptor expression in THP-1 
macrophages and impact of TLR receptor stimulation on proinflammatory cytokine production.  
Data represents the mean ± standard deviation of 4 independent experiments.  *p<0.001 
A) A representative flow cytometry histogram of human THP-1 macrophages demonstrating 
enhanced TLR2 and CD44 receptor expression, compared to TLR4. 
B) Impact of Pam3CSK4 (Pam; TLR2 ligand) and Lipopolysaccharide (LPS; TLR4 ligand) 
treatments on interleukin-1 beta (IL-1b) production in THP-1 macrophages.  
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C) Impact of Pam3CSK4 and LPS treatment on tumor necrosis factor alpha (TNF-a) production 
in THP-1 macrophages. 
 
 
Fig. 2.2 Binding of hyaluronan (HA) to recombinant human CD44 and TLR2 receptors and impact 
of HA treatment on TLR2 receptor stimulated nuclear translocation of nuclear factor kappa B 
(NFkB).  TLR2 receptor stimulation was performed using Pam3CSK4 (Pam; 5 ng/mL).  
A) Concentration-dependent binding of HA to immobilized CD44 or TLR2 receptors using a 
microplate assay format.  HA exhibited a concentration-dependent binding to CD44 receptor and 
no significant binding to TLR2 receptor. 
B) Impact of HA treatment (250 and 500 µg/mL), a CD44 antibody (CD44 Ab 2.5 µg/mL) or an 
isotype control (IC; 2.5 µg/mL) on TLR2 induced NFkB nuclear translocation in THP1 XBlue 
monocytes.  HA and CD44 Ab treatments reduced TLR2 induced NFkB nuclear translocation.  
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Data represents the mean ± standard deviation of 4 independent experiments.  *p<0.001; 
**p<0.01. 
C) Impact of HA treatment (100, 250 and 500 µg/mL) on TLR2 induced NFkB p65 subunit nuclear 
translocation in THP-1 macrophages.  HA (250 and 500 µg/mL) treatments reduced NFkB nuclear 
translocation in THP-1 macrophages.  Data represents the mean ± standard deviation of 4 
independent experiments.  *p<0.001; **p<0.01. 
D) Protein phosphatase 2A (PP2A) mediates HA’s inhibition of NFkB p65 subunit nuclear 
translocation in THP-1 macrophages.  Okadaic acid (OKA; 5 nM), a potent inhibitor of PP2A, 
abolished the inhibitory effect of HA (250 µg/mL) on NFkB p65 subunit translocation in THP-1 
macrophages.  Data represents the mean ± standard deviation of 4 independent experiments.  
*p<0.001; **p<0.01. 
 
Fig. 2.3 Impact of hyaluronan (HA) (100, 500 and 1,000 µg/mL), CD44 antibody (CD44 Ab; 2.5 
µg/mL) or isotype control (IC; 2.5 µg/mL) treatments on TLR2 receptor induced interleukin-1 beta 
(IL-1b) or tumor necrosis factor alpha (TNFa) gene expression and production in THP-
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macrophages.  Data represents the mean ± standard deviation of 4 independent experiments.  
*p<0.001; **p<0.01; ***p<0.05. 
A) HA (500 and 1,000 µg/mL) treatments reduced TLR2 induced IL-1b gene expression. 
B) HA (500 and 1,000 µg/mL) treatments reduced TLR2 induced TNF-a gene expression. 
C) HA (500 and 1,000 µg/mL) treatments reduced TLR2 induced IL-1b production. 
D) HA (500 and 1,000 µg/mL) treatments reduced TLR2 induced TNF-a production. 
E) CD44 Ab treatment reduced TLR2 induced IL-1b production. 
F) CD44 Ab treatment reduced TLR2 induced TNF-a production. 
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Fig. 2.4 Impact of toll-like receptor 2 (TLR2) receptor stimulation on CD44 gene expression and 
CD44 levels in THP-1 macrophages and the role of hyaluronan (HA).  TLR2 receptor stimulation 
was performed using Pam3CSK4 (Pam; 5ng/mL) for 24 hours.  Data represents the mean ± 
standard deviation of 4 independent experiments.  *p<0.001; **p<0.01. 
 A) HA (100, 500 and 1,000 µg/mL) treatments reduced TLR2 induced CD44 gene expression in 
THP-1 macrophages. 
B) A representative flow cytometry histogram demonstrating increased CD44 protein levels in 
TLR2 stimulated THP-1 macrophages.  HA (500 and 1,000 µg/mL) treatments reduced CD44 
levels in TLR2 stimulated THP-1 macrophages. 
C) Semi-quantitative analysis of mean fluorescence intensities of CD44 receptor following TLR2 
stimulation in the absence or presence of HA (100, 500 or 1,000 µg/mL).  TLR2 stimulation 
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increased CD44 protein in THP-1 macrophages and HA (500 and 1,000 µg/mL) treatments 
reduced CD44 protein. 
 
 
Fig. 2.5 Impact of CD44 receptor knockdown on toll-like receptor 2 (TLR2) receptor stimulated 
proinflammatory cytokine production in THP-1 macrophages and nuclear factor kappa B (NFkB) 
p65 subunit nuclear translocation.  TLR2 receptor stimulation was performed using Pam3CSK4 
(Pam; 5ng/mL).  Data represents the mean ± standard deviation of 4 independent experiments.  
*p<0.001.  ***p<0.05. 
A) CD44 siRNA treatment resulted in reduced CD44 gene expression compared to negative 
control (NC) siRNA treatment or control. 
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B) A representative flow cytometry histogram demonstrating reduced CD44 protein levels in 
CD44 siRNA-treated THP-1 macrophages compared to control. 
C) Semi-quantitative analysis of mean fluorescence intensities of CD44 or TLR2 receptors in 
THP-1 macrophages following CD44 knockdown.  CD44 knockdown resulted in approximately 
60% reduction in CD44 levels.  
D) CD44 siRNA treatment reduced TLR2 stimulated NFkB p65 subunit nuclear translocation. 
E) CD44 siRNA treatment reduced TLR2 stimulated interleukin-1 beta (IL-1b) production in 
THP-1 macrophages. 
F) CD44 siRNA treatment reduced TLR2 stimulated tumor necrosis factor alpha (TNF-a) 
production in THP-1 macrophages. 
 
 
Fig. 2.6 Impact of hyaluronan (HA) treatment on toll-like receptor 2 (TLR2) induced interleukin-
1 beta (IL-1b) and tumor necrosis factor alpha (TNF-a) production in CD44 siRNA-treated, 
negative control (NC) siRNA-treated and untreated control THP-1 macrophages.  TLR2 
stimulation was performed using Pam3CSK4 (Pam; 5ng/mL) for 24 hours.  HA treatment was 
performed at 500 µg/mL.  Data represents the mean ± standard deviation of 4 independent 
experiments.  *p<0.001; n.s.: not significant. 
A) HA treatment reduced TLR2 induced IL-1b production in untreated control and NC siRNA-
treated THP-1 macrophages.  HA treatment did not alter IL-1b levels in CD44 siRNA-treated 
macrophages.  
 
 49 
B) HA treatment reduced TLR2 induced TNF-a production in untreated control and NC siRNA-
treated THP-1 macrophages.  HA treatment did not alter TNF-a levels in CD44 siRNA-treated 
macrophages. 
 
Fig. 2.7 Impact of toll-like receptor 2 (TLR2) receptor stimulation on tumor necrosis factor alpha 
(TNF-a) production by CD44+/+ and CD44-/- murine bone marrow derived macrophages 
(BMDMs) and dose-dependent effect of HA on CD44+/+ BMDMs.  TLR2 stimulation was 
performed using Pam3CSK4 (Pam; 5ng/mL) for 6 hours.  Data represents the mean ± standard 
deviation of 4 independent experiments.  *p<0.001; **p<0.01. 
    
A) A representative flow cytometry histogram of murine BMDMs showing positive staining for 
CD11b and F4/80 surface markers. 
B) TLR2 receptor activation dose-dependently increased TNF-a production by murine CD44+/+ 
BMDMs compared to CD44-/- BMDMs. 
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C) HA (250 and 500 µg/mL) treatments reduced TLR2 induced TNF-a production by murine 
CD44+/+ BMDMs. 
 
 
Fig. 2.8 Activation of toll-like receptors 2 and (TLR2 and TLR4) by synovial fluid (SF) aspirates 
from patients with advanced osteoarthritis (OA) and role of CD44 in modulating THP-1 
macrophages activation by OA SF.  OA SF (3.75µL per well) were incubated with TLR2-HEK or 
TLR4-HEK cells in HEK detection media for 48 hours followed by measuring the 630 nm 
absorbance.  THP-1XBlue macrophages were incubated with OA SF in the absence or presence of 
a TLR2-specific, CD44-specific, or isotype control (IC) antibody (2.5µg/mL) for 48 hours 
followed by measuring 630 nm absorbance.  Normal SF specimens were used as controls.  
*p<0.001; **p<0.01. 
A) Activation of TLR2 and TLR4 receptors by OA SF (n=12).  A total of 8 samples activated both 
TLR2 and TLR4 receptors, compared to untreated controls. 
B) Activation of THP-1XBlue macrophages by OA SF (n=8) and the impact of CD44-specific or 
TLR2-specific antibody treatments.  CD44 and TLR2 antibody treatments reduced OA SF induced 
macrophage activation. 
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ABSTRACT 
Osteoarthritis (OA) is characterized by synovitis and synovial fibrosis.  Synoviocytes are 
fibroblast-like resident cells of the synovium that are activated by TGF-b to proliferate, migrate 
and produce extracellular matrix.  Synoviocytes secrete hyaluronan (HA) and proteoglycan-4 
(PRG4).  HA reduced synovial fibrosis in vivo and the Prg4-/- mouse exhibits synovial hyperplasia.  
We investigated the antifibrotic effects of increased intracellular cAMP in TGF-β stimulated 
human OA synoviocytes.  TGF-β1 stimulated collagen I (COL1A1), α-SMA, TIMP-1, PLOD2 
expression and procollagen I, α-SMA, HA and PRG4 production, migration and proliferation of 
OA synoviocytes were measured.  Treatment of OA synoviocytes with forskolin (10μM) increased 
intracellular cAMP levels and reduced TGF-β1 stimulated COL1A1, α-SMA and TIMP-1 
expression, with no change in PLOD2 expression.  Forskolin also reduced TGF-b1 stimulated 
procollagen I and α-SMA content, as well as synoviocyte migration and proliferation.  Forskolin 
(10μM) increased HA secretion, PRG4 expression and production.  A cell permeable cAMP analog 
reduced COL1A1 and α-SMA expression and enhanced HA and PRG4 secretion by OA 
synoviocytes.  HA and PRG4 reduced α-SMA expression and content and PRG4 reduced COL1A1 
expression and procollagen I content in OA synoviocytes.  Prg4-/- synovium exhibited increased 
α-SMA, COL1A1 and TIMP-1 expression as compared to Prg4+/+ synovium.  Prg4-/- synoviocytes 
demonstrated strong α-SMA and collagen type I staining while these were undetected in Prg4+/+ 
synoviocytes, and was reduced with PRG4 treatment.  We conclude that increasing intracellular 
cAMP levels in synoviocytes mitigates synovial fibrosis through enhanced production of HA and 
PRG4, possibly representing a novel approach for treatment of OA synovial fibrosis.  
      Keywords: cAMP, fibrosis, PRG4, HA, Osteoarthritis, synoviocytes. 
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3.1 INTRODUCTION 
Hallmarks of osteoarthritis (OA) include cartilage degeneration, subchondral bone remodeling, 
and synovitis [112, 118, 156].  Major abnormalities in the OA synovium include synovial 
hyperplasia, inflammatory cell infiltration, angiogenesis and fibrosis [157-160].  Synovial fibrosis 
is a common feature in advanced OA that contributes to joint pain and stiffness [110, 161].  The 
TGF-b1 family and its associated signaling pathways play an essential role in maintaining 
homeostasis in healthy joints [162].  However, TGF-b1 switches to a pathologic role in OA joints 
that drives synovial fibrosis [163].  TGF-b1 upregulates the expression of synovial collagen type 
1, tissue inhibitor of metalloproteinase 1 (TIMP-1), and procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2 (PLOD2) [163, 164].  The net result is an increase in collagen I formation, an 
increase in collagen crosslinks and a reduction in collagen turnover [163, 164].  
The normal synovium contains two types of intimal cells: type A macrophages and type B 
fibroblasts, or synoviocytes [115].  In synoviocytes, TGF-b1 induces fibrotic changes 
characterized by cell proliferation and collagen type I accumulation [165].  Additionally, TGF-b1 
promotes the differentiation of OA synoviocytes into a myofibroblast-like phenotype, 
characterized by the expression of alpha smooth muscle actin (α-SMA) [166].  Synoviocytes 
produce hyaluronan (HA), a glycosaminoglycan synthesized by membrane-bound hyaluronan 
synthase (HAS) with three isoforms identified to date (HAS1, HAS2 and HAS3) [167].  
Synoviocytes also produce proteoglycan-4 (PRG4), a heavily glycosylated mucinous glycoprotein 
[168, 169].  HA and PRG4 play important roles in joint lubrication [170].  HA and PRG4 may also 
play a role in joint fibrosis as HA treatment reduced synovial fibrosis in vivo and findings in 
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synovial tissues from Prg4-/- mice include increased synovial thickening and a proliferative 
capacity for Prg4-/- synoviocytes under basal and cytokine stimulated conditions [81, 92, 154].   
Cyclic adenosine monophosphate (cAMP) is a pleiotropic intracellular second messenger 
generated by adenylyl cyclase (AC) enzymes in response to G-protein coupled receptor (GPCR) 
activation [62].  The antifibrotic effect of cAMP has been described in fibroblasts from multiple 
origins and include inhibition of fibroblast proliferation, reduction in fibroblast migration and 
reduced synthesis of extracellular matrix components [171-174].  The role of cAMP in regulating 
TGF-b1’s fibrotic response in synoviocytes is unknown.  Our aim was to study the impact of 
forskolin, an AC activator, on the expression and production of α-SMA, collagen type I, and 
expression of TIMP-1, PLOD2, HAS isoforms, PRG4 and production of HA and PRG4 in a model 
of TGF-β1 stimulated OA synoviocytes.  Given the potential involvement of HA and PRG4 in 
synovial fibrosis, we also studied the antifibrotic effect of HA and PRG4 in human and murine 
synoviocytes.  We hypothesized that increasing intracellular cAMP exerts an antifibrotic effect in 
OA synoviocytes and promotes HA and PRG4 production. 
3.2 MATERIALS AND METHODS 
3.2.1 Ethical approvals:  
Animal breeding and tissue harvest was approved by the IACUC committee at Rhode Island 
Hospital.     
3.2.2 Patient characteristics and experimental approach 
OA synoviocytes (500,000 cells per vial; Cell Applications, USA) were isolated from synovial 
tissues from de-identified OA patients undergoing knee replacement (n=10; median age = 63; 
range: 54 to 69).  Six patients were female.  Five patients were Caucasian, and the other five were 
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unspecified.  Synoviocytes were received in their second passage.  OA Synoviocytes were cultured 
in 75 cm2 culture flasks in DMEM media supplemented with 10% FBS and were used between the 
third and sixth passages to avoid alterations in patterns of gene expression [175, 176].  
Experimental data are represented as the mean ± S.D. of 3-6 biological replicates.    
We initially studied cAMP generation in OA synoviocytes using a 0.01 to 10µM forskolin 
concentration range.  The 10µM was selected based on previous studies [177, 178].  Following 
confirmation of cAMP accumulation by forskolin, we determined its effect on a-SMA, collagen 
type I, TIMP-1 and PLOD2 expression in TGF-ß1 stimulated OA synoviocytes.  The antifibrotic 
effect of intracellular cAMP accumulation in OA synoviocytes was further confirmed using a cell 
permeable cAMP analog, 8-bromo cAMP.   To further appreciate the antifibrotic effect of 
forskolin, we evaluated the impact of cAMP generation on HAS isoform expression and HA 
production, as well as PRG4 expression and production.  Based on forskolin’s observed effect on 
HA and PRG4, we studied the antifibrotic effect of HA and PRG4 in human OA synoviocytes, 
murine Prg4-/- synoviocytes as well as fibrosis markers in the Prg4-/- synovium.  Finally, we 
studied the efficacy of forskolin in mitigating TGF-b1 stimulated OA synoviocyte migration and 
proliferation.  
3.2.3 cAMP generation in OA synoviocytes by forskolin  
cAMP levels were measured in OA synoviocytes using the cADDis assay (Montana Molecular, 
USA).  The assay utilizes a fluorescent cAMP sensor that measures changes in intracellular cAMP 
levels.  An increase in intracellular cAMP levels results in a reduction in green fluorescence.  OA 
synoviocytes (10,000 cells per well) were cultured overnight in sterile 96-well clear-bottom black 
plates in the presence of a recombinant mammalianized baclovirus expressing the cAMP sensor 
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according to manufacturer’s recommendations.  Subsequently, media supernatants were replaced 
with Dulbecco’s phosphate-buffered saline (DPBS; Thermo Fisher Scientific, USA) (200μL per 
well).  Forskolin (Sigma-Aldrich, USA) at a final concentration of 0.01, 0.1, 1, and 10μM, vehicle 
and a positive control were added and fluorescence intensity using 494/522 nm wavelengths was 
measured every 30 seconds over 30 minutes.  Data is presented as the ratio of fluorescence 
intensity reduction at each time point to fluorescence intensity at baseline.       
3.2.4 Gene expression studies 
OA synoviocytes (300,000 cells per well) were treated with TGF-b1 (1ng/mL; R&D systems, 
USA) in serum-free DMEM ± forskolin (0.1, 1, or 10μM), 8-bromo cAMP (Sigma Aldrich) (100 
and 500µM), human synoviocyte PRG4 (apparent MW 280 kDa as a monomer; 100μg/mL) [179] 
and/or high molecular weight HA (MW >950 kDa; R&D Systems) (100 μg/mL) for 24 hours 
followed by RNA extraction, cDNA synthesis and qPCR as previously described [155].  The cycle 
threshold (Ct) value of target genes were normalized to the Ct value of GAPDH in the same sample, 
and the relative expression was calculated using the 2-ΔΔCt method [134].  Target genes included 
α-SMA (ACTA2), collagen type I (COL1A1), TIMP-1, PLOD2, HAS1, HAS2, HAS3, and PRG4 
(primers and probes were obtained from Thermo Fisher Scientific).  Data are presented as fold 
expression of target genes in the different experimental groups compared to untreated controls.  
3.2.5 a-SMA and procollagen type I quantitation 
OA synoviocytes were seeded in cell culture dishes (20.8 cm2) at 1.0 x 106 cells per dish until 
confluence.  OA synoviocytes in serum-free DMEM media (5 ml per dish) were treated with TGF-
b1 (1ng/mL) ± forskolin (10µM), PRG4 (100µg/mL) or HA (100µg/mL) for 24 hours.  Cell protein 
extraction was performed using M-PER reagent supplemented with protease and phosphatase 
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cocktail inhibitor (Thermo Fisher Scientific) and quantified using micro BCA assay (Thermo 
Fisher Scientific).   
Gel electrophoresis was performed using 10% PAGE gels (Bio-Rad) and 10µg protein per well.  
Following transfer, membranes were blocked with 5% non-fat dry milk for 2 hours at room 
temperature.  Membranes were probed with anti-a-SMA (1:1,000 dilution) and anti-GAPDH 
(1:5,000 dilution) (Abcam) overnight in tris-buffered saline tween 20 (TBS-T).  Following 
washing with TBS-T, membranes were incubated with horseradish peroxidase (HRP)-conjugated 
anti-rabbit (1:5,000 dilution) antibody for 1 hour at room temperature (Abcam).  Protein bands 
were developed using Lumigen ECL Ultra reagent (Lumigen, USA) and visualized using Bio-Rad 
ChemiDoc XRS+ system (Bio-Rad).  Bands of interest were selected and quantified using Image 
J software.  The ratio of a-SMA band intensities to corresponding GAPDH band intensities of the 
different experimental groups were calculated and normalized to controls.     
Procollagen I content in OA synoviocytes was determined using an ELISA (Abcam and R&D 
Systems).  A total of 5 µg protein in 100 µL buffer was used in each experimental group and 
procollagen I concentrations (pg/mL) were divided by 50 and expressed as procollagen I protein  
per µg protein. 
3.2.6 Immunocytostaining of a-SMA in OA synoviocytes 
OA synoviocytes (200,000 cells per well) were cultured on collagen type I-coated 12 mm glass 
coverslips for 48 hours in DMEM supplemented with 10% FBS.  Subsequently, cells were treated 
with TGF-β1 (1 ng/ml) ± forskolin (10μM) for 48 hours in serum-free DMEM.  Synoviocytes were 
fixed in 10% neutral buffered formalin for 10 min followed by washing twice with PBS.  Cells 
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were permeabilized for 5 min using 0.01% Triton X100 in PBS and blocked using 2%BSA for 1 
hour at room temperature.  Probing was performed using FITC-conjugated anti a-SMA antibody 
(1:100; Abcam) and Alexa Fluor 594 conjugated anti-alpha tubulin antibody (1:500; Abcam) 
overnight at 4oC.  Following washing with PBS, cells were mounted with DAPI mounting medium 
(Abcam) for 1 hour and viewed under a confocal microscope.     
3.2.7 HA, PRG4 and HAS1 quantitation  
HA concentrations:  OA synoviocytes (300,000 cells per well) in serum-free DMEM were treated 
with TGF-b1 (1ng/mL) ± forskolin (10μM) for 24 hours.  Media supernatants were collected and 
assayed for HA using a quantitative assay kit (R&D systems).  In a separate set of experiments, 
OA synoviocytes (300,000 cells per well) in serum-free DMEM were treated with TGF-b1 
(1ng/mL) ± 8-bromo cAMP (100 and 500μM) for 24 hours.  HA concentrations were determined 
as described above. 
PRG4 concentrations: OA synoviocytes (20,000 cells per well) were seeded in sterile 96 well 
plates for 48 hours followed by treatment with TGF-β1 (1ng/mL) ± forskolin (10μM) for 48 hours.  
PRG4 concentrations, normalized to cell density, were determined in media supernatants as 
previously described [155].  In a separate set of experiments, OA synoviocytes (300,000 cells per 
well) in serum-free DMEM were treated with TGF-b1 (1ng/mL) ± 8-bromo cAMP (100 and 
500μM) for 24 hours.  PRG4 concentrations were determined as described above. 
HAS1 content: OA synoviocytes were seeded and treated as described for a-SMA and procollagen 
type I.  HAS1 content in protein isolates were determined using an ELISA (MyBioSource, USA).  
A total of 1μg total protein in 100μL volume was added to the wells of the ELISA plate.  HAS1 
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concentrations (ng/mL) were divided by 10 and expressed as HAS1 content (ng) per μg total 
protein.  
3.2.8 HAS1 knockdown and its impact on forskolin-induced HA secretion in OA synoviocytes 
OA synoviocytes (300,000 cells per well) in Opti-MEM reduced serum medium (Thermo Fisher 
Scientific) were treated with a HAS1 small interfering RNA (siRNA) (Thermo Fisher Scientific) 
(25 pmoles per well) or a non-targeted negative control (NC) siRNA (25 pmoles per well) (Thermo 
Fisher Scientific) for 48 hours.  Transfection was performed using Lipofectamine RNAiMAX 
(Thermo Fisher Scientific) per manufacturer’s recommendations.  To confirm HAS1 knockdown, 
HAS1 expression was determined as described above.  In a separate set of experiments, HAS1 
knockdown in OA synoviocytes was performed followed by media change to serum-free DMEM 
and stimulation with TGF-β1 (1ng/mL) ± forskolin (10μM) for 24 hours.  Subsequently, HA 
concentrations were determined in media supernatants as described above. 
3.2.9 Gene expression studies in Prg4+/+ and Prg4-/- synovial tissues and immunocytostaining 
of murine synoviocytes  
The phenotype of the Prg4-/- mouse has been previously reported [180], and is characterized by 
cartilage degeneration and a hyperplastic synovium contributing to joint failure [180].  The Prg4-
/- and Prg4+/+ mouse colonies are maintained by Dr. Jay at Rhode Island Hospital.  Prg4-/- mouse 
is also commercially available (stock #025737; The Jackson Laboratory, Maine, USA).  Synovial 
tissues were isolated from male Prg4-/-  and Prg4+/+ mice (8-10 weeks old).  The skin and 
surrounding tissues of the knee joints were removed.  The joint capsule was cut open along both 
sides of the patella under a stereo microscope and the synovium from the lateral and medial sides 
was carefully isolated.  A total of 15 Prg4+/+ and 15 Prg4-/- male mice were used in this study.   
Synovial tissues were harvested from every mouse and tissues from 3 mice were randomly pooled 
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into one sample, generating 5 pooled samples in each genotype.  RNA isolation, cDNA synthesis 
and qPCR were performed as previously described.  Genes of interest included ACTA2, COL1A1, 
TIMP-1 and PLOD2 with GAPDH as an internal reference gene (Thermo Fisher Scientific).  
Prg4+/+ and Prg4-/- synoviocytes were isolated as previously described [86].  Synovial tissues from 
male Prg4+/+ and Prg4-/- mice (15 animals per genotype) were used to isolate the synoviocytes.  
Synoviocytes were plated onto sterile chamber slides (Thermo Fisher Scientific) at a density of 1.0 
x 106 cells per well and allowed to adhere for 24 hrs. Synoviocytes were incubated with human 
synoviocyte PRG4 (100 μg/mL) in serum-free DMEM for 24 hours followed by washing with PBS 
and cell fixation with 4% formalin.  Probing was performed using anti-a-SMA antibody (1:100 
dilution) or anti-collagen type I antibody (1:200 dilution) (Abcam) at 4oC overnight.  Following 
washing with PBS, cells were incubated with Cy3 goat anti-rabbit IgG antibody (1:200 dilution; 
Thermo Fisher Scientific) for 1 hr at room temperature in the dark.  Following washing with PBS, 
Alexa Fluor 488-conjugated phalloidin, a filamentous actin (F-actin) probe (1:125 dilution; 
Thermo Fisher Scientific), was added for 20 min in the dark.   Cells were subsequently mounted 
with DAPI mounting medium (Vector Labs) and viewed under a fluorescent microscope (Nikon 
E 800). 
3.2.10 Basal and TGF-β1 induced OA synoviocytes proliferation and migration  
In sterile 96 well plates, OA synoviocytes (10,000 cells per well) were cultured in serum-free 
DMEM media and incubated with forskolin (3, 10 and 30µM) ± TGF-β1 (1ng/mL) for 48 hours at 
37oC.  Cell proliferation was determined using the MTT reagent (Sigma).  OA synoviocytes 
(100,000 cells per well) were seeded in 24-well culture plates in DMEM+10% FBS for 72 hours.  
A 1,000 µL pipette tip was used to perform a scratch in the confluent synoviocyte monolayer.  
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TGF-β1 (1ng/mL) stimulation was performed in serum-free DMEM ± forskolin (10µM) for 48 
hours.  Subsequently, media was aspirated and cells were stained (Cell Biolabs, USA) followed 
by imaging using all-in-one fluorescence microscope (Keyence, USA).  A region of interest (ROI) 
was defined and the scratch width was measured at multiple locations in the ROI.  The mean 
scratch width was calculated and used to estimate the mean scratch area.  Data is presented as the 
ratio of the scratch areas of the different experimental groups to the scratch area at baseline.   
3.2.11 Statistical Analyses 
Variables were initially tested for normality.  Normally distributed variables were compared using 
Student’s t-test for two groups or analysis of variance with Tukey’s post-hoc test for more than 
two groups.  Variables that did not satisfy the normality assumption were tested using ANOVA 
on the ranks.  Statistical analysis of gene expression data was performed using DCt values (Ct 
target gene-Ct GAPDH) for each gene of interest.  Significance level was set at 0.05.  
3.3 RESULTS 
3.3.1 Forskolin treatment increased intracellular cAMP, reduced ACTA2, COL1A1, TIMP-1 
expression and reduced a-SMA and procollagen type I in TGF-β1 stimulated OA 
synoviocytes  
A representative dose-response of forskolin is shown in figure 3.1A.  Treatment with forskolin 
(0.01μM) did not increase intracellular cAMP while the 0.1, 1 and 10μM forskolin treatments 
resulted in detectable increases in cAMP.  Forskolin (10μM) increased intracellular cAMP 
compared to vehicle (fig. 3.1B; p<0.001) (n=3 patients).  TGF-β1 induced ACTA2, COL1A1, 
TIMP-1 and PLOD2 expression (fig. 3.1C through F; p<0.001 versus control for the 4 genes) (n=4 
patients).  Forskolin treatment reduced ACTA2 (fig. 3.1C; p<0.001), COL1A1 (fig. 3.1D; p<0.01), 
and TIMP-1 (fig. 3.1E; p<0.001) expression compared to TGF-β1 alone.  Forskolin treatment did 
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not alter TGF-β1 stimulated PLOD2 expression (fig. 3.1F; p=0.833).  Forskolin did not alter basal 
COL1A1 (p=0.623), TIMP-1 (p=0.802) or PLOD2 (p=0.752) expression.  In contrast, forskolin 
reduced basal ACTA2 expression (p=0.018).  
A Western Blot and semi-quantitative analysis of α-SMA using GAPDH as a loading control are 
shown in fig. 3.1G and fig. 3.1H, respectively.  TGF-β1 increased α-SMA protein in OA 
synoviocytes compared to control (fig. 3.1H; p<0.001) (n=6 patients).  Forskolin reduced TGF-β1 
stimulated α-SMA production (p=0.013).  Forskolin alone did not alter basal α-SMA content 
(p=0.660).  Representative confocal images of TGF-β1-treated OA synoviocytes ± forskolin is 
shown in figure 3.1I.  Control OA synoviocytes exhibited a positive α-SMA staining, and the 
appearance of a myofibroblast-like phenotype in a number of cells.  TGF-β1 treatment resulted in 
stronger α-SMA staining and the appearance of myofibrils and this was markedly reduced with 
forskolin co-treatment.  TGF-β1 increased procollagen type I protein compared to control (fig. 
3.1J; p<0.01) (n=3 patients).  Forskolin reduced TGF-β1 linked procollagen type I production 
(p=0.015), and did not alter basal procollagen type I (p=0.991).  
3.3.2 Forskolin treatment enhanced HA secretion and modulated HAS isoform gene 
expression and HAS1 knockdown attenuated forskolin’s effect on HA production in TGF-β1 
stimulated OA synoviocytes 
HA concentrations were higher in TGF-β1 treated OA synoviocytes and forskolin-treated OA 
synoviocytes compared to untreated controls (fig. 3.2A; p<0.001 for both comparisons) (n=4 
patients).  HA concentrations in the TGF-β1 + forskolin group were higher than HA concentrations 
in the TGF-β1 or forskolin alone groups (p<0.001 for both comparisons).  TGF-β1 induced HAS1 
(fig. 3.2B; p<0.001) and HAS2 (fig. 3.2C; p<0.001) with no effect on HAS3 (fig. 3.2D; p=0.719) 
expression in OA synoviocytes (n=4 patients).  Forskolin treatment upregulated basal HAS1, HAS2 
and HAS3 expression (p<0.001 for all comparisons).  Combined treatment of TGF-β1 and 
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forskolin increased HAS1 expression over TGF-β1 alone (fig. 3.2B; p=0.026).  In contrast, HAS2 
expression in the TGF-β1 + forskolin group was lower than HAS2 expression in the TGF-β1 group 
(fig. 3.2C; p=0.024).  
The total cellular HAS1 content was higher in TGF-β1 (p=0.021) and TGF-β1 + forskolin 
(p<0.01) treatments compared to control (fig. 3.2E) (n=4 patients).  HAS1 content was not 
different between TGF-β1 + forskolin and TGF-β1 alone groups (p=0.971).  Similarly, there was 
no difference in HAS1 between forskolin and control groups (p=0.303).  HAS1 expression was 
reduced by approximately 68% in OA synoviocytes transfected with HAS1 siRNA (fig. 3.2F; 
p<0.01) (n=4 OA patients).  HA concentrations in TGF-β1 stimulated HAS1 knockdown OA 
synoviocytes were not different from unstimulated HAS1 knockdown OA synoviocytes (fig. 3.2G; 
p=0.962) (n=4 patients).  Similarly, HA concentrations in TGF-β1 + forskolin treated HAS1 
knockdown OA synoviocytes were not different from HA concentrations in TGF-β1 treated HAS1 
knockdown OA synoviocytes (p=0.514).  Finally, HA concentrations in TGF-β1 + forskolin 
treated OA synoviocytes were higher than HA concentrations in TGF-β1 + forskolin treated HAS1 
knockdown OA synoviocytes (p<0.001).    
3.3.3 Forskolin treatment enhanced PRG4 expression and secretion in TGF-β1 stimulated 
OA synoviocytes 
TGF-β1 induced PRG4 expression (fig. 3.3A; p<0.001) and increased PRG4 production by OA 
synoviocytes (fig. 3.3B; p<0.01) (n=4 patients).  Forskolin did not alter basal PRG4 expression 
(fig. 3.3A; p=0.063) or PRG4 production (fig. 3.3B; p=0.996) in OA synoviocytes.  PRG4 
expression in the TGF-β1 + forskolin group was higher than TGF-β1 alone (fig. 3.3A; p=0.037).  
Correspondingly, PRG4 concentrations were higher in the TGF-β1 + forskolin group compared to 
the TGF-β1 group (fig. 3.3B; p=0.031).   
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3.3.4 Impact of PRG4 and HA treatments on ACTA2 and COL1A1 expression and a-SMA 
and procollagen type I in TGF-β1 stimulated OA synoviocytes 
ACTA2 expression was lower in the TGF-β1 + PRG4 group compared to TGF-β1 alone (fig. 3.3C; 
p<0.001) (n=4 patients).  Similarly, ACTA2 expression in the TGF-β1+ HA and TGF-β 1 + PRG4 
+ HA groups was lower than ACTA2 expression in TGF-β1 alone (p<0.001 for both comparisons).  
COL1A1 expression was lower in the TGF-β1 + PRG4 group compared to TGF-β1 + HA (p<0.01) 
or TGF-β1 alone (p<0.001) (fig. 3.3D) (n=4 OA patients).  In contrast, HA treatment did not alter 
TGF-β1 induced COL1A1 expression (p=0.897).  COL1A1 expression in the TGF-β1 + PRG4 + 
HA group was lower than TGF-β1 (p<0.001) and TGF- β1 + HA (p<0.01) groups. 
A Western Blot and semi-quantitative analysis of α-SMA using GAPDH as a loading control are 
shown in 3.3E and 3.3F, respectively.  α-SMA content was lower in TGF-β1 + PRG4 (fig. 3.3F; 
p<0.01) and in TGF-β1 + HA (p<0.01) compared to TGF-β1 alone (n=4 patients).  Procollagen 
type I content was lower in TGF-β1 + PRG4 compared to TGF-ß1 alone (fig. 3.3G; p<0.01) (n=4 
patients).  There was no difference in procollagen type I content between TGF-β1 + HA and TGF-
β1 groups (p=0.059). 
3.3.5 A cell permeable cAMP analog treatment reduced ACTA2 and COL1A1 expression and 
enhanced HA and PRG4 secretion in TGF-β1 stimulated OA synoviocytes 
TGF-β1 induced ACTA2 and COL1A1 expression in OA synoviocytes (fig. 3.4A and 3.4B; 
p<0.001 against control for both genes).  8-bromo cAMP (100µM) treatment did not significantly 
alter TGF-β1 induced ACTA2 and COL1A1 expression (p>0.05 for both comparisons).  In contrast, 
8-bromo cAMP (500µM) treatment reduced ACTA2 (p<0.001) and COL1A1 (p<0.001) 
expression in TGF-β1 stimulated OA synoviocytes (n=3 OA patients).  HA and PRG4 media 
concentrations in TGF-β1 + 8-bromo cAMP (500µM) group were significantly higher than 
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corresponding concentrations in TGF-β1 only group (fig. 3.4C and 3.4D; p<0.001 for both 
comparisons) (n=3 OA patients).  
3.3.6 ACTA2, COL1A1 and TIMP-1 expression was higher in Prg4-/- synovial tissues and 
human synoviocyte PRG4 treatment reduced α-SMA and collagen type I staining in Prg4-/- 
synoviocytes 
  Expression of ACTA2 (p=0.021), COL1A1 (p<0.001) and TIMP-1 (p<0.01) was higher in Prg4-
/- synovia compared to Prg4+/+ synovia (fig. 3.5A).  In contrast, PLOD2 expression was lower in 
Prg4-/- tissues compared to Prg4+/+ tissues (p<0.01). 
Merged images of α-SMA and collagen type I stained Prg4+/+ and Prg4-/- synoviocytes is shown 
in figure 3.5B.  We observed strong α-SMA and collagen type I staining in Prg4-/- synoviocytes.  
α-SMA staining co-localized with F-actin staining.    In contrast, there was no detected α-SMA or 
collagen type I staining in Prg4+/+ synoviocytes.  PRG4 treatment reduced α-SMA and collagen 
type I staining in Prg4-/- synoviocytes. 
3.3.7 Forskolin reduced TGF-β1 induced OA synoviocyte proliferation and migration  
Forskolin (3 µM and 10µM) treatments did not alter basal OA synoviocyte proliferation (fig. 3.6A; 
p=0.891 and p=0.117)  (n=4 patients).  In contrast, the 30µM treatment increased basal OA 
synoviocyte proliferation compared to untreated control (p<0.01).  TGF-β1 stimulated OA 
synoviocyte proliferation (fig. 3.6B; p<0.001) (n=4 patients).  OA synoviocyte proliferation in the 
TGF-β1 + forskolin (30µM) group was lower than TGF-β1 alone (p<0.001), TGF-β1 + forskolin 
(3µM) (p<0.01) or TGF-β1 + forskolin (10µM) (p<0.01).  There was no difference in cell 
proliferation between TGF-β1 + forskolin (10µM) and TGF-β1 alone (p=0.063).  Representative 
wound scratch images are show in figure 3.6C.  TGF-β1 enhanced OA synoviocyte migration (fig. 
3.6D; p<0.01) (n=4 patients).  OA synoviocyte migration in the TGF-β1 + forskolin (10µM) group 
 
 66 
was lower than in the TGF-β1 only group (p<0.01).  There was no difference in cell migration 
between forskolin treated and untreated OA synoviocytes (p=0.887). 
3.4 DISCUSSION 
In this paper, we show that TGF- β1 resulted in excess collagen type I production, induction of 
TIMP-1 and PLOD2 expression and a-SMA upregulation, together with stimulating OA 
synoviocyte migration and proliferation.  Forskolin, by virtue of its ability to generate cAMP, 
reduced collagen production and blunted TIMP-1 expression while inhibiting synoviocyte 
proliferation and migration.  PLOD2 induction in osteoarthritic synoviocytes is consistent with its 
established role in mediating synovial collagen crosslinking [181, 182].  Forskolin did not alter 
PLOD2 expression, which may be related to the TGF-β1’s signaling pathways.  Remst et al have 
shown that in OA synoviocytes, an ALK 1/2/3/6 inhibitor completely blocked TGF-β1 induced 
collagen type I expression whereas TGF-β1 induced PLOD2 expression was only slightly reduced 
[183]. 
OA synoviocytes proliferate in response to various mitogenic stimuli [155, 184, 185].  In our 
experiments, TGF-β1 induced cell proliferation with a magnitude comparable to what has been 
previously reported [184].  Forskolin, at the treatment level that inhibited migration, exhibited a 
marginal antiproliferative effect and a higher concentration was needed to observe significant 
antagonism of TGF-β1’s mitogenic effect.  This might be due to a low proliferative capacity of 
OA synoviocytes.  In the absence of TGF-β1, forskolin acted as a mitogen to produce a low, yet 
significant, stimulation of proliferation.  Forskolin directly binds to AC and generates cAMP from 
ATP [186].  The increase in cAMP results in activation of protein kinase A (PKA) dependent and 
independent pathways [186, 187].  In the presence of growth factors, forskolin activates cAMP-
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dependent PKA which interferes with Raf-1 activation and signaling to blunt cell proliferation 
[67].  PKA also activates CREB, which can compete for cofactors with SMAD-mediated 
transcription stimulated by TGF-β1[177]. In the absence of growth factor, PKA-dependent and 
independent pathways stimulate cAMP-mediated cell proliferation [188].   
We measured a-SMA in OA synoviocytes from human patients and forskolin addition consistently 
attenuated TGF-β1-stimulated a-SMA expression.  a-SMA is a specific marker of myofibroblasts 
[189, 190].  Myofibroblasts are effector cells in fibrosis that possess enhanced ability to produce 
collagen, proliferate and migrate [189, 190].  We have shown that forskolin treatment appeared to 
markedly reduce TGF-β1’s induced myofibroblast-like phenotype in OA synoviocytes.  The causal 
role that myofibroblasts may play in synovial fibrosis is understudied and unclear.  Steenvoorden 
et al reported that a-SMA staining was only found in blood vessels in synovia from healthy 
individuals [191].  Interestingly, TGF- β1 stimulation of normal synoviocytes increased collagen 
type I expression with no effect on a-SMA expression or production [191].  Mattey et al have 
shown that TGF-β1 or IL-4 treatments trigger differentiation of OA synoviocytes into 
myofibroblast-like cells, characterized by a-SMA expression in vitro [166].  Evidence relating 
myofibroblasts to changes occurring in joint fibrosis was reported by Sasabe et al [192].  Using a 
rat knee contracture model, myofibroblasts expressing a-SMA were detected as early as 1 week 
from joint immobilization and this was associated with increased collagen type I expression and 
joint capsule fibrosis [192].  We have also detected a-SMA protein in Prg4-/- synoviocytes with 
no a-SMA signal in normal murine synoviocytes.  The positive a-SMA signal in Prg4-/- knockout 
synoviocytes is associated with phenotypical changes in the synovium including synovial lining 
thickening and enhanced synoviocyte proliferation [81]. 
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TGF-β1 induced HAS1 and HAS2 expression with no effect on HAS3, and enhanced HA secretion 
by OA synoviocytes.  Synoviocytes contain higher levels of HAS1 message compared to HAS2 
with HAS3 being the least abundant [193].  Earlier reports are in agreement with our finding that 
TGF-β1 stimulation of arthritic synoviocytes resulted in a higher HAS1/HAS2 transcript ratio 
above control level and that in turn resulted in higher extracellular HA levels [184, 193].  Our data 
suggests that the majority of TGF-β1 linked HA secretion is mediated by HAS1, as HAS1 
knockdown diminished extracellular HA concentrations.  Co-treatment with forskolin increased 
the HAS1/HAS2 transcript ratio above the corresponding TGF-ß1 ratio with greater HA secretion 
over 24 hours.  The increase in HAS1 mRNA in forskolin-treated synoviocytes did not translate 
to increased HAS1 cellular pool.  This might be related to the rate at which the message is being 
translated.  Furthermore, the majority of HAS1 cellular fraction is inactive and is found in the 
cytoplasm either diffused or partially co-localized with the Golgi apparatus, whereas the plasma 
membrane-bound fraction is small and is catalytically active [178].  Therefore, the possibility that 
the newly synthesized HAS1 enzyme, in response to forskolin treatment, could have been 
trafficked to the membrane resulting in increasing the rate of HA synthesis could not be ruled out.  
Assessing the impact of forskolin on membrane-bound HAS1 level and activity was technically 
challenging and was not feasible to perform.  Our data should also be considered in the context 
that other factors e.g. post-translational modifications, availability of precursors and regulation of 
HAS activity will likely contribute to the amount of HA secreted by the OA synoviocytes[193] . 
Increasing intracellular cAMP resulted in increasing PRG4 expression and production by OA 
synoviocytes in the setting of TGF-b1 stimulation.  This contextual effect is due to CREB 
stimulation which was previously shown to enhance PRG4 production by superficial zone articular 
chondrocytes [194].  PRG4 is a mucin-like glycoprotein synthesized by synoviocytes and 
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superficial zone articular chondrocytes with a heavily glycosylated central domain and an N- and 
C-termini [195].  The mouse Prg4 gene is highly homologous to the human Prg4 gene [196].  
Human and mouse Prg4 genes each consist of 12 exons and the N- and C-termini are highly 
conserved across species [196].   PRG4 exists in the synovial fluid in monomeric or multimeric 
forms and functions as a boundary lubricant [195, 197].  PRG4 binds to CD44, the HA receptor, 
and exerts an anti-inflammatory effect in OA synoviocytes [86, 155].  PRG4 also acts in an 
autocrine manner to regulate OA synoviocyte proliferation [155].  We have found that PRG4 and 
HA had equivalent efficacy in reducing a-SMA content in osteoarthritis synoviocytes.  However, 
PRG4, at a physiologically-relevant concentration [150], was more efficacious than HA in 
reducing collagen I expression and production, indicative of a potential role in antagonizing 
profibrotic alterations in synovial tissues.  This function is likely related to its interaction with the 
CD44 receptor, given that HA reduced synovial fibrosis in a CD44-mediated manner [92].  PRG4 
reduced collagen I and a-SMA staining in Prg4-/- synoviocytes.  The link between PRG4 
expression and synovial fibrosis is further illustrated by the upregulation of collagen type I, TIMP-
1 and a-SMA in the Prg4-/- synovium.  As laying excess collagen type I is a prominent feature in 
synovial fibrosis, the strong immunocytostaining for collagen type I in Prg4-/- synoviocytes, 
coupled with other synovial changes, support a fibrotic Prg4-/- synovium.  We did not include 
human normal synoviocytes in our study design.  Furthermore, we did not examine the efficacy of 
forskolin or PRG4 in an in-vivo model of synovial fibrosis.   
In summary, our data demonstrate that forskolin; a diterpene produced by the roots of the Indian 
plant Coleus forskohili [186], increases intracellular cAMP levels and produces an antifibrotic 
effect in OA synoviocytes.  Increasing intracellular cAMP levels directly via treatment with a cell 
permeable cAMP analog recapitulated the antifibrotic effect of forskolin.  Forskolin reduces 
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collagen type I expression and procollagen type I production and inhibits TGF-β1 linked fibroblast 
migration and proliferation.  Forskolin also increased HA and PRG4 secretion by OA 
synoviocytes; an effect that may contribute to its overall antifibrotic efficacy. Approaches that 
increase cAMP levels in synoviocytes can promote an antifibrotic phenotype and may be a novel 
approach for slowing the progression of synovial fibrosis in OA. 
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3.9 FIGURES 
 
Fig. 3.1 Impact of forskolin (FsK) treatment on intracellular cyclic adenosine monophosphate 
(cAMP) levels, basal and transforming growth factor beta 1 (TGF-β1)-induced alpha smooth 
muscle actin (ACTA2), collagen I (COL1A1), tissue inhibitor of metalloproteinase 1 (TIMP-1) and 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) gene expression and alpha smooth 
muscle action (a-SMA) and procollagen type I production in osteoarthritic (OA) synoviocytes.  
TGF-β1 (1ng/ml) stimulation of OA-FLS was performed for 24 hours in all experiments except a-
SMA immunocytostaining (stimulation was performed using 1 ng/ml TGF-β1 for 48 hours). Data 
is presented as the mean ± S.D. of experiments utilizing OA synoviocytes from different patients.  
*p<0.001; **p<0.01; ***p<0.05.   
A.  Representative dynamic change in intracellular cAMP levels in OA synoviocytes following 
treatment with FsK (0.01, 0.1, 1 and 10μM).  FsK treatment (0.1, 1 and 10μM) resulted in 
detectable cAMP levels in OA synoviocytes.  The cAMP signal was detected using a cAMP-
specific sensor.  B. cAMP levels were elevated in FsK (10μM)-treated OA synoviocytes (n=3 
patients). C.  FsK treatment (1 and 10μM) reduced TGF-β1 induced ACTA2 expression (n=4 
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patients). D.  FsK treatment (10μM) reduced TGF-β1 induced COL1A1 expression (n=4 patients). 
E.  FsK treatment (10μM) reduced TGF-β1 induced TIMP-1 expression (n=4 patients).  F.  Fsk 
treatment (10µM) did not alter TGF-β1 induced PLOD2 expression (n=4 patients).  G.  Western 
Blot of α-SMA in control, TGF-β1, TGF-β1 + FsK and FsK-treated OA synoviocytes.  GAPDH 
was used as loading control.  H. Semi-quantitative densitometry analysis of α-SMA normalized to 
GAPDH and expressed as ratio to control in cell extracts of control, TGF-β1, TGF-β1 + FsK and 
FsK-treated OA synoviocytes.  FsK (10μM) treatment reduced TGF-β1 linked increase in α-SMA 
in OA synoviocytes (n=6 patients).  I.  FsK (10μM) treatment reduced α-SMA staining and 
myofibroblast-like phenotype in TGF-β1 stimulated OA synoviocytes.  J. Procollagen type I 
content in cell extracts of control, TGF-β1, TGF-β1 + FsK and FsK-treated OA synoviocytes.  Data 
was normalized to total protein content.  FsK (10μM) treatment reduced TGF-β1 linked increase 
in procollagen type I content in OA synoviocytes (n=3 patients).             
 
 
Fig. 3.2 Impact of forskolin (FsK; 10μM) treatment on basal and transforming growth factor beta 
1 (TGF-β1)-induced hyaluronan (HA) production, expression of hyaluronan synthase isoforms 1, 
2, and 3 (HAS1, HAS2 and HAS3) and the role of HAS1 in mediating TGF-β1 and FsK-linked HA 
production in osteoarthritic (OA) synoviocytes.  Data is presented as the mean ± S.D. of 
experiments utilizing OA synoviocytes from 4 patients.  *p<0.001; **p<0.01; ***p<0.05; n.s.: 
non significant.    
A. Hyaluronan concentrations in control, TGF-β1, TGF-β1 + FsK, and FsK-treated OA 
synoviocytes. B. FsK treatment enhanced TGF-β1 induced HAS1 expression.  C. FsK treatment 
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reduced TGF-β1 induced HAS2 expression.  D. FsK treatment increased basal HAS3 expression in 
OA synoviocytes.  E. HAS1 protein content in cell extracts of control, TGF-β1, TGF-β1 + FsK 
and FsK-treated OA synoviocytes.  Data was normalized to total protein content.  There was no 
difference in HAS1 protein between TGF-β1 and TGF-β1 + FsK treatments. F.  HAS1 expression 
was reduced in HAS1 siRNA-treated OA synoviocytes compared to untreated control and negative 
control siRNA (NC siRNA)-treated OA synoviocytes.  G. FsK and/or TGF-β1 treatments did not 
significantly change hyaluronan production following HAS1 knockdown in OA synoviocytes.  
 
Fig. 3.3 Impact of forskolin (FsK; 10μM) treatment on basal and transforming growth factor beta 
1 (TGF-β1) induced proteoglycan-4 (PRG4) gene expression and production by osteoarthritic 
(OA) synoviocytes and efficacy of human synoviocyte PRG4 (100µg/ml) and hyaluronan (HA) 
(100µg/ml) in modulating TGF-β1 induced expression and production of alpha smooth muscle 
actin and collagen type I in OA synoviocytes.  Data is presented as the mean ± S.D. of experiments 
utilizing OA synoviocytes from 4 patients.   *p<0.001; **p<0.01; ***p<0.05.   
A.  TGF-β1 increased PRG4 expression and FsK treatment enhanced TGF-ß1’s effect.  B. FsK 
treatment enhanced TGF-β1 linked PRG4 production by OA synoviocytes.  C. PRG4 and/or HA 
treatments reduced TGF-β1 induced alpha smooth muscle actin gene (ACTA2) expression in OA 
synoviocytes.  D.  PRG4 treatment reduced TGF-β1 induced collagen type I (COL1A1) gene 
expression in OA synoviocytes.  E. Western Blot of α-SMA in control, TGF-β1, TGF-β1 + PRG4 
(100µg/ml) and TGF-β1 + HA (100µg/ml) treated OA synoviocytes.  GAPDH was used as loading 
control.  F. Semi-quantitative densitometry analysis of α-SMA normalized to GAPDH and 
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expressed as ratio to control in cell extracts of control, TGF-β1, TGF-β1 + PRG4 and TGF-β1 + 
HA treated OA synoviocytes.  PRG4 and HA treatments reduced TGF-β1 linked increase in α-
SMA in OA synoviocytes.  G. Procollagen type I content in cell extracts of control, TGF-β1, TGF-
β1 + PRG4 and TGF-β1 + HA-treated OA synoviocytes.  Data was normalized to total protein 
content.  PRG4 treatment reduced TGF-β1 linked increase in procollagen type I content in OA 
synoviocytes.             
 
Fig. 3.4 Impact of 8-bromo cAMP (8-Br-cAMP; 100 and 500µM) treatment on basal and 
transforming growth factor beta 1 (TGF-b1)-induced alpha smooth muscle actin (ACTA2) and 
collagen I (COL1A1) expression and hyaluronan (HA) and proteoglycan-4 (PRG4) secretion in 
osteoarthritic synoviocytes.  Data is presented as the mean ± S.D. of experiments utilizing OA 
synoviocytes from 3 patients.  *p<0.001.  A. 8-Br-cAMP (500µM) reduced TGF-β1 linked ACTA2 
expression in OA synoviocytes.  B.  8-Br-cAMP (500µM) reduced TGF-β1 linked COL1A1 
expression in OA synoviocytes.  C.  8-Br-cAMP (500µM) increased HA secretion in TGF- 
β1stimulated OA synoviocytes.  D.  8-Br-cAMP (500µM) increased PRG4 secretion in TGF- 
β1stimulated OA synoviocytes.   
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Fig. 3.5 Gene expression of alpha smooth muscle actin (ACTA2), collagen type I (COL1A1), 
tissue-inhibitor of metalloproteinase-1 (TIMP-1) and procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2 (PLOD2) in synovial tissues isolated from Prg4+/+ and Prg-/- mice and 
immunocytostaining of alpha smooth muscle actin (a-SMA) and collagen type I in Prg+/+ and 
Prg4-/- synoviocytes and impact of human synoviocyte PRG4 treatment.  *p<0.001; **p<0.01; 
***p<0.05. 
A. ACTA2, COL1A1 and TIMP-1 expression in Prg4-/- synovial tissues was higher than Prg4+/+ 
synovial tissues.  PLOD2 expression in Prg4-/- synovial tissues was lower than Prg4+/+ synovial 
tissues.  Each group contained 5 samples with each sample generated by pooling synovial tissues 
from 3 mice.  
B. Merged images depicting a-SMA and collagen type I protein immunostaining in isolated 
Prg4+/+ synoviocytes and Prg4-/- synoviocytes (bright orange) and counterstained with F-actin 
[198] and DAPI (blue).  a-SMA and collagen type I staining was detected in Prg4-/- synoviocytes 
(white arrows) and no staining was detected in Prg4+/+ synoviocytes.  a-SMA and collagen type I 
staining intensities were reduced by human synoviocyte PRG4 treatment for 24 hours.  Scale = 
50µm.    
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Fig. 3.6 Impact of forskolin (FsK) treatment on basal and transforming growth factor beta 1 (TGF-
β1) induced proliferation and migration of osteoarthritic (OA) synoviocytes.  Data is presented as 
the mean ± S.D. of experiments utilizing OA synoviocytes from 4 patients.  *p<0.001; **p<0.01; 
***p<0.05.  Scale = 1,000 μM.  A.   FsK (30μM) treatment enhanced basal OA synoviocyte 
proliferation.  B.  FsK (30μM) treatment reduced TGF-β1-induced OA synoviocyte proliferation. 
C.  Representative images showing baseline and 48-hour basal, TGF-β1, TGF-β1 + FsK and FsK 
alone induced OA synoviocyte migration using an in vitro scratch assay.  D. FSK (10μM) 
treatment reduced TGF-β1 stimulated OA synoviocyte migration.  
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ABSTRACT 
Background: Synovial tissue fibrosis is common in advanced OA with features including 
presence of stress fiber-positive myofibroblasts and deposition of cross-linked collagen type-I.  An 
antifibrotic effect in OA synoviocytes was associated with PRG4 secretion and native synovial 
PRG4 reduced collagen content in OA synoviocytes.  PRG4 is a ligand of the CD44 receptor.  Our 
objective was to examine the role of PRG4-CD44 interaction in regulating synovial tissue fibrosis 
in vitro and in vivo. 
Methods:  OA synoviocytes were treated with TGF-b ± PRG4 for 24 hours and a-SMA content 
was determined using immunofluorescence.  Rhodamine labeled rhPRG4 was incubated with OA 
synoviocytes ± anti-CD44 or isotype control antibodies and cellular uptake of rhPRG4 was 
determined following a 30-min incubation and a-SMA expression following a 24-hour incubation.  
HEK-TGF-b cells were treated with TGF-b ± rhPRG4 and Smad3 phosphorylation was 
determined using immunofluorescence and TGF-b/Smad pathway activation was determined 
colorimetrically.  We probed for stress fibers and focal adhesions (FAs) in TGF-b treated murine 
fibroblasts and fibroblast migration was quantified ± rhPRG4.  Synovial expression of fibrotic 
markers: a-SMA, collagen type-I and PLOD2 in Prg4 gene trap (Prg4GT) and recombined Prg4GTR 
animals was studied at 2 and 9 months of age.  Synovial expression of a-SMA and PLOD2 was 
determined in 2-months old Prg4GT/GT&Cd44-/- and Prg4GTR/GTR&Cd44-/- animals.    
Results: PRG4 reduced a-SMA content in OA synoviocytes (p<0.001).  rhPRG4 was internalized 
by OA synoviocytes via CD44 and CD44 neutralization attenuated rhPRG4’s antifibrotic effect 
(p<0.05).  rhPRG4 reduced pSmad3 signal in HEK-TGF-b cells (p<0.001) and TGF-b/Smad 
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pathway activation (p<0.001).  rhPRG4 reduced the number of stress fiber-positive 
myofibroblasts, FAs mean size, and cell migration in TGF-b treated NIH3T3 fibroblasts (p<0.05).  
rhPRG4 inhibited fibroblast migration in a macrophage and fibroblast co-culture model without 
altering active or total TGF-b levels.  Synovial tissues of 9-months old Prg4GT/GT animals had 
higher a-SMA, collagen type-I and PLOD2 (p<0.001) content and Prg4 re-expression reduced 
these markers (p<0.01).  Prg4 re-expression also reduced a-SMA and PLOD2 in CD44-deficient 
mice.       
Conclusion: PRG4 is an endogenous antifibrotic modulator in the joint and its effect on 
myofibroblast formation is mediated by CD44, but CD44 is not required to demonstrate an 
antifibrotic effect in vivo. 
Keywords: Proteoglycan-4, CD44, SMA, synovial fibrosis, myofibroblast 
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4.1 INTRODUCTION 
Osteoarthritis (OA) is the most prevalent type of musculoskeletal disorder in patients 60 years or 
older [199-201].  OA is a leading cause of pain and disability and patients with symptomatic knee 
OA are at an increased risk of all-cause mortality [202-204].  The etiology of OA is complex where 
joint trauma, obesity and genetics, among other risk factors, contribute to disease development 
[205-208].   OA affects the whole joint with manifestations that include degeneration of articular 
cartilage and the meniscus, abnormal bone remodeling, and synovial inflammation [160, 209].  
Macroscopic evidence of synovial inflammation or synovitis is a common finding in up to 74% of 
patients with knee OA of different grades and 95% of patients with moderate to severe OA [112, 
210, 211].  OA synovitis is likely caused by an innate immune response, mediated by the toll-like 
receptors 2 and 4 (TLR2 and TLR4) in the synovium, and resultant expression of inflammatory 
cytokines, chemokines and matrix degrading enzymes [140, 212-215].  The extent of synovitis is 
a strong predictor of OA progression across multiple studies, and therefore treating synovial 
inflammation is a potentially important target for therapeutic intervention, especially during the 
early stage of OA [112, 157, 216].  
The normal synovium is composed of a cellular intimal layer and a subintimal connective tissue 
layer [112, 115].  The intimal layer is usually 1-4 cells in thickness with two types of cells; type A 
macrophages and type B synovial fibroblasts, with macrophages making up a smaller percentage 
of cells in the intimal layer of the healthy synovium [115].  Synovial fibroblasts synthesize 
hyaluronic acid (HA), a glycosaminoglycan, and proteoglycan-4 (PRG4), a mucinous 
glycoprotein, which are major components of synovial fluid (SF) with important roles in joint 
lubrication [195, 217].  In synovitis, synovial membranes become hyperplastic with increased 
accumulation of macrophages and other inflammatory cells, along with subintimal fibrosis and 
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angiogenesis [112, 160, 161].  Synovial fibrosis can be considered a maladaptive healing response 
to chronic synovitis which is characterized by upregulation of collagen type-I expression, 
fibroblast transition to a myofibroblast-like phenotype through de-novo expression of alpha 
smooth muscle actin (a-SMA) and enhanced migratory behavior, and upregulation of procollagen-
lysine, 2-oxogluterate 5-dioxygenase 2 (PLOD2) leading to accumulation of cross-linked collagen 
in the synovium [164, 218].  These pathological changes are induced in the OA synovium by 
transforming growth factor beta (TGF)-b1 and its associated signaling pathways [162, 183].  
Synovial fibrosis independently contributes to joint pain and stiffness observed in advanced OA 
[161, 219].   
In a recent study, we demonstrated that increasing intracellular adenosine 3¢, 5¢-cyclic 
monophosphate (cAMP), using forskolin, reduced collagen type-I, PLOD2 and a-SMA expression 
in TGF-b stimulated osteoarthritic fibroblast-like synoviocytes (OA FLS) and reduced fibroblast 
to myofibroblast transition, as evidenced by blocking stress fiber formation [220].  Associated with 
this antifibrotic effect was an increase in HA and PRG4 production by OA FLS, whereby native 
synovial human PRG4 reduced procollagen type-I level in OA FLS [220].  Furthermore, 
synoviocytes from Prg4 null mice displayed more extensive collagen type-I and a-SMA 
immunostaining compared to synoviocytes from Prg4 competent mice [220].  In a separate study, 
we have also shown that PRG4 is a ligand for the HA receptor, CD44 [154].  We have also reported 
that PRG4-CD44 interaction inhibited interlukin-1 beta (IL-1b) induced OA FLS proliferation and 
expression of matrix degrading enzymes [155], via the inhibition of nuclear factor kappa b (NF-
kB) nuclear translocation mediated by blocking inhibitory kappa b (IkB) degradation [155].  
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It remains unknown whether PRG4 has a role in regulating fibroblast to myofibroblast transition 
and associated cell migration in the fibrotic synovium.  Furthermore, it is yet to be determined 
whether PRG4 regulates synovial fibrosis in vivo and whether this role is due to its interaction with 
the CD44 receptor.  Using recombinant human proteoglycan-4 (rhPRG4),we aimed to study the 
role of PRG4 in regulating fibroblast to myofibroblast transition and modulating fibroblast 
migration in response to exogenous TGF-b or co-incubation with lipopolysaccharide (LPS) 
stimulated macrophages.  We also studied the role of PRG4-CD44 interaction, and more 
specifically CD44-mediated cellular uptake of PRG4, in the regulation of myofibroblast formation 
in vitro and progression of synovial fibrosis in vivo.  We hypothesized that PRG4 regulates 
fibroblast to myofibroblast transition and prevents synovial fibrosis in a CD44-dependent manner. 
4.2 METHODS 
4.2.1 Impact of PRG4 and HA treatments on ACTA2 expression, α-SMA immunostaining, 
and stress fiber formation in osteoarthritic fibroblast-like synoviocytes (OA FLS) and role 
of CD44 in mediating the effect of rhPRG4 in TGF-β stimulated OA FLS 
OA FLS (Cell Applications, USA) were isolated from synovial tissues from de-identified patients 
undergoing knee replacement surgery (n=4; 2 males and 2 females; 62-69 years old).  Cells were 
received in their second passage and were cultured as previously described [213].  OA FLS were 
used between the 3rd and 6th passages to avoid alterations in gene expression pattern and cell 
proliferation rate [176].  OA FLS (300,000 cells/well) in serum-free DMEM media were treated 
with recombinant human TGF-b1 (R&D Systems, USA) (1ng/mL) ± native human synovial PRG4 
(apparent mol mass 280 kDa as a monomer; 100µg/mL) [179] or high molecular weight hyaluronic 
acid (HA; ~1,200 kDa; R&D Systems; 100µg/mL) for 24 hours.  RNA isolation, cDNA synthesis 
and quantitative PCR were performed as previously described [220].  The cycle threshold (Ct) 
value of α-SMA (ACTA2) was normalized to the Ct value of GAPDH in the same sample, and the 
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relative expression was calculated using the 2-ΔΔCt method [134].  All primers and probes utilized 
in our study are commercially available (Thermo Fisher Scientific, USA).  
Assessment of a-SMA content in OA FLS was conducted using immunofluorescence and 
determination of corrected total cell fluorescence (CTCF) using a Nikon E600 fluorescence 
microscope.  OA FLS (200,000 cells/well) were cultured on collagen type I-coated 22 mm glass 
coverslips for 48 hours in DMEM medium + 10% fetal bovine serum (FBS).  Cells were treated 
with TGF-b1 (1ng/mL) ± PRG4 or HA (100µg/mL for both treatments) for 48 hours in serum-free 
DMEM medium.  Subsequently, cells were fixed in 10% neutral buffered formalin for 15 min and 
washed twice with phosphate buffered saline (PBS).  Cells were permeabilized using 0.01% Triton 
X-100 in PBS and blocked using 2% bovine serum albumin (BSA; Sigma Aldrich, USA) in PBS 
for 2 hours at room temperature.  Probing for α-SMA was performed using FITC-conjugated anti-
α-SMA antibody (1:100 dilution; Abcam, USA) and counterstained using Alexa Fluor 594-
conjugated anti-α-tubulin antibody (1:100 dilution: Abcam) overnight at 4oC.  Following washing 
with PBS, cells were mounted on DAPI mounting shield (Abcam) and CTCF was quantified using 
4 different fields per slide and mean CTCF was calculated.  Presence of stress fibers in OA FLS 
was also evaluated. 
Recombinant human PRG4 (rhPRG4; apparent mol mass 240 kDa) is an endotoxin-free full- 
length product produced by CHO-M cells (Lubris, Framingham, USA) [221].  Rhodamine labeling 
of rhPRG4 was performed using the Pierce NHS-Rhodamine Antibody Labeling Kit (Thermo 
Fisher Scientific).  OA FLS (200,000 cells/well) were cultured on collagen type-I coated cover 
slips and incubated with rhodamine-rhPRG4 (25µg/mL) ± anti-CD44 or isotype control (IC) 
antibodies (2µg/mL for both antibodies; Abcam) for 30 minutes.  Cells were pre-incubated with 
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the antibodies for 1-hour prior to rhPRG4 addition.  Subsequently, cells were washed twice with 
PBS and mounted on DAPI mounting media and CTCF was quantified as described above.  In 
another set of experiments, OA FLS (300,000 cells/well) were treated with TGF-b1 (1ng/mL) ± 
rhPRG4 (100µg/mL) ± anti-CD44 or IC antibodies (2µg/mL for both antibodies) for 24 hours 
followed by determination of ACTA2 expression as described above.          
4.4.2 CD44-dependent uptake of rhPRG4, Smad3 phosphorylation and regulation of TGF-
b/Smad pathway activation in TGF-b stimulated HEK Blue-TGF-b cells 
HEK Blue-TGF-b is an engineered reporter cell line produced by transfecting human embryonic 
kidney (HEK) cells with TGF-b receptor 1 (TGF-b R1), Smad3 and Smad4 genes (Invivogen, 
USA).  TGF-b1-treatment results in phosphorylation of Smad3 (pSmad3) and Smad4 (pSmad4), 
translocation to the nucleus and expression of secreted alkaline phosphatase (SEAP).  The activity 
of SEAP can be detected colorimetrically in media supernatants using a specific substrate (Quanti 
Blue) at 620-655 nm (Invivogen).  HEK-TGF-b cells (500,000) were plated onto sterile chamber 
slides and incubated with rhodamine-rhPRG4 (25µg/mL) for 1 hour ± anti CD44 or IC antibodies 
(2µg/mL for both antibodies).  Cells were pre-incubated with the antibodies for 1-hour prior to 
rhPRG4 addition.  Subsequently, cells were washed with PBS and intracellular CTCF was 
determined as described above.  In another set of experiments, rhodamine labeled rhPRG4 
(25µg/mL) was incubated with HEK-TGF-b cells and CD44 was probed using FITC-conjugated 
anti-CD44 antibody (Abcam) and CD44 [198] and rhPRG4 (red) co-localization was examined 
using a confocal microscope. 
Immunostaining of pSmad3 was performed using an anti-Smad3 antibody that detects 
phosphorylated serine residues (1:1,000 dilution overnight at 4oC; Abcam).  HEK-TGF-b cells 
were stimulated with TGF-b1 ± rhPRG4 (150µg/mL) for 1 hour.  Subsequently, cells were fixed, 
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washed with PBS and permeabilized as described above.  Following probing with anti-pSmad3 
antibody, cells were washed with PBS and incubated with goat anti-rabbit IgG (Alexa Fluor 488) 
(1:1,000 dilution for 1 hour at room temperature; Abcam).  Cells were subsequently washed with 
PBS and green immunofluorescence was quantified across all experimental groups.  To investigate 
the impact of rhPRG4 on TGF-b/Smad pathway activation, HEK-TGF-b cells (100,000 cells/well) 
were cultured in sterile 96 well plates ± TGF-b1 (1ng/mL) ± rhPRG4 (50, 100 or 150µg/mL) for 
24 hours in Quanti-Blue media and the 655 nm absorbance intensity was determined.  Data are 
presented as fold absorbance intensities across experimental groups normalized to untreated 
controls. 
4.2.3 TGF-b induction of stress fibers, focal adhesions (FAs) and cell migration in murine 
NIH3T3 fibroblasts, comparison of stress fibers and FAs in Prg4+/+ and Prg4-/- synovial 
fibroblasts and role of rhPRG4 in regulating fibroblast migration  
Murine fibroblasts (NIH3T3; ATCC; 20,000 cells/well) were cultured on collagen type I-coated 
22-mm glass coverslips for 24 hours in DMEM supplemented with 10% bovine calf serum (BCS). 
NIH3T3 cells were starved in DMEM containing 1% BCS for 24 hours. Murine fibroblasts were 
treated with murine TGF-b1 (1ng/ml) ± rhPRG4 (200µg/mL) for 24 hours in serum-free DMEM.  
Subsequently, fibroblasts were fixed using neutral buffered formalin, washed with PBS, 
permeabilized using 0.1% triton X-100 and probed using an anti-a-SMA (marker of stress fibers; 
1:1,000) or anti-vinculin (marker of FA complex; 1:1,000) overnight at 4oC.  After washing with 
PBS, cells were incubated with goat anti rabbit IgG (Alexa Fluor®488) at 1:1,000 dilution for 1 
hour at 4°C.  Rhodamine-labeled phalloidin (cytoskeleton label; 1:1,000) was added with the 
secondary antibody.  All antibodies were obtained from Abcam.  Cells were washed and mounted 
with DAPI medium for 2 hours and viewed under a confocal microscope.  The number of stress 
fiber-positive fibroblasts was determined by a blinded investigator.  At least 100 cells over at least 
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5 different fields were evaluated, and the percentage of stress-fiber positive fibroblasts was 
calculated.  Separately, mean fibroblast cell spread area was determined using NIS-Elements 
imaging software (Nikon).  The number and mean size of FAs per cell were determined using 
ImageJ software as previously described [222].  Fibroblast migration was determined using a 
scratch assay.  A 1,000 µL pipette tip was used to perform a uniform scratch in the confluent 
NIH3T3 fibroblast monolayer.  TGF-b (1ng/mL) stimulation was performed for 48 hours ± 
rhPRG4 (200µg/mL).  Subsequently, cells were washed and stained (Cell Biolabs) and imaged 
using an all-in-one fluorescence microscope (Keyence).  A region of interest was defined and 
scratch widths were determined across multiple locations.  Cell migration was expressed as percent 
wound closure across different experimental groups as previously described [223].   
The phenotype of Prg4-/- mice is characterized by synovial membrane hyperplasia, chondrocyte 
apoptosis, and cartilage surface fibrillation [180].  The Prg4-/- mouse colony is maintained by Dr. 
Gregory Jay at Rhode Island Hospital (RIH) and is commercially available (stock no. 025737; 
JAX, USA).  All animal experiments were approved by the IACUC committee at RIH and all 
experiments were performed according to all applicable guidelines and regulations.  Synoviocyte 
isolation from Prg4-/- and Prg4+/+ synovial tissues was performed as previously described [154, 
220].  Prg4-/- and Prg4+/+ synoviocytes were plated onto sterile chamber slides (Thermo Fisher 
Scientific) and allowed to adhere for 48 hours.  Subsequently, cells were stained for a-SMA and 
vinculin as described above.  The mean size of FAs per cell in Prg4-/- and Prg4+/+ synoviocytes 
was determined as described above.  Prg4-/- and Prg4+/+ synoviocytes were seeded in 6 well plates 
and a scratch was performed in the confluent cell monolayer as described above.  Basal synovial 
fibroblast migration of both genotypes was quantified over 48 hours ± rhPRG4 (200µg/mL), anti-
CD44 (2µg/mL) or IC (2µg/mL) antibodies as previously described [223].  
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4.2.4 Generation of Active TGF-b in lipopolysaccharide-stimulated murine macrophage 
J774A and NIH3T3 fibroblast co-culture and impact of rhPRG4 treatment on fibroblast 
migration 
Murine J774A macrophages (ATCC) were cultured in DMEM medium + 10% FBS.  Macrophages 
(300,000 cells in DMEM medium + 10% FBS) were stimulated with lipopolysaccharide (LPS; 
Invivogen) (5µg/mL) for 24 hours.  Subsequently, murine macrophages were washed five times 
with DMEM medium and transferred to the top chamber of a transwell co-culture system (0.4 µm 
pore size; Sigma Aldrich).  Murine NIH3T3 cells were seeded in the lower chamber of the 
transwell system and a scratch was performed as described above.  NIH3T3 migration was 
determined following a 48-hour incubation of fibroblasts with macrophages in the co-culture 
system as described above ± rhPRG4 (200µg/mL).  Active and total TGF-b media levels were 
determined using an ELISA (R&D Systems).  
4.2.5 Age-dependent expression of fibrotic markers in synovial tissues from Prg4GT/GT 
animals and the role of PRG4/CD44 interaction in modulating synovial fibrosis in vivo 
The Prg4 gene-trap (Prg4GT) mouse colony is maintained by Dr. Gregory Jay at RIH and is 
commercially available (stock no. 025740; JAX) [224].  Prg4GT animal is a genetically engineered 
PRG4-deficient mouse where the Prg4 expression can be restored via CRE-mediated 
recombination [224].  The Prg4GT/GT mouse recapitulates the hallmark findings in Prg4-/- mouse, 
namely synovial tissue hyperplasia and cartilage surface fibrillations and recombination in 3-
weeks old animals improved but did not completely normalize joint pathological findings [224].  
In our studies, recombination (Prg4GTR/GTR) occurred in 3-weeks old animals via intraperitoneal 
injection of tamoxifen (0.1 mg/g in 100µL corn oil vehicle) daily for 10 days.  We compared gene 
expression and immunostaining of fibrotic markers: a-SMA, COL1A1 (collagen type-I) and 
PLOD2 in 2-months old Prg4GT/GT, 2-months old Prg4GTR/GTR, 9-months old Prg4GT/GT and 9-
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months old Prg4GTR/GTR animals.  ACTA2, COL1A1 and PLOD2 expression levels in murine 
synovial tissues were performed as previously described [220].  Tissues from each three 
consecutive mice were pooled and underwent RNA isolation, generating five pooled samples in 
each experimental group.  Separately, animal joints (n=5 in each group) underwent decalcification 
and paraffin-embedded sectioning as previously described [224].  Immunostaining of synovial 
tissues was performed using primary antibodies against a-SMA, COL1A1 or PLOD2 (1:1,000 
dilutions performed overnight at 4oC) (All antibodies were purchased from Abcam).  
Subsequently, sections were washed and incubated with goat anti-rabbit IgG (Alexa Fluor 488) 
(1:1,000 dilution) for 1 hour and fluorescence intensities (expressed as lumens/mm2) were 
quantified using a fluorescence microscope. 
To appreciate the significance of PRG4 and CD44 interaction in the context of fibrotic markers’ 
expression in the synovium, Prg4GT/GT animals were crossed with Cd44-/- mice (stock no. 005085; 
JAX) [135] to generate Cd44-/-&Prg4GT/GT animals.  Recombination occurred in 3-weeks old 
animals to generate Cd44-/-&Prg4GTR/GTR animals as described in the last paragraph.  Histological 
analyses of joints harvested from 2-months old animals (at least 4 animals per group) were 
performed as described above, using Cd44+/+&Prg4GT/GT animals from the same litters as controls.  
We probed synovial tissues for the following fibrotic markers: a-SMA and PLOD2 using specific 
primary antibodies (1:1,000 dilutions) followed by goat anti-rabbit IgG (Alexa Fluor 488) and 
quantitation of fluorescence intensities (expressed as lumens/mm2) as described above.    
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4.3 Statistical Analyses    
Target gene expression was statistically evaluated by comparing DCt (Ct value of target gene- Ct 
value of GAPDH in the same sample) values of different experimental groups.  Statistical 
significance comparing two groups or multiple groups with parametric data was assessed by 
Student’s t test or ANOVA followed by post-hoc multiple comparisons (Tukey’s post-hoc test).  
Statistical significance comparing two groups or multiple groups with nonparametric data was 
assessed by Rank Sum test or ANOVA on the ranks.  A p value of < 0.05 was considered 
statistically significant.  Data are presented as scatter plots with mean and standard deviations 
highlighted.    
4.4 RESULTS 
4.4.1 PRG4 reduced ACTA2 expression and stress fiber formation in osteoarthritic 
fibroblast-like synoviocytes (OA FLS) and CD44 was involved in the uptake of rhPRG4 by 
OA FLS, whereas rhPRG4-CD44 interaction affected ACTA2 expression in response to 
TGF-b 
PRG4 and HA demonstrated equivalent efficacy in reducing ACTA2 expression in OA FLS (Fig. 
4.1A).  Both treatments reduced ACTA2 expression compared to the positive control TGF-b1 
(p<0.001 for TGF-b1 + PRG4 or TGF-b1 + HA against TGF-b1 alone).  In addition to reducing 
ACTA2 expression, PRG4 reduced a-SMA content in OA FLS (p<0.001 versus TGF-b1 alone; 
Fig. 4.1C).  A similar effect was also observed for HA treatment (p<0.001 versus TGF-b1 alone; 
Fig. 4.1C).  The effect of PRG4 was biologically significant with approximately 52% reduction in 
mean a-SMA immunofluorescence compared to TGF-b1 alone.  In addition to reducing a-SMA 
in OA FLS, PRG4 and HA treatments prevented the formation of stress fibers in OA FLS in 
response to TGF-b1 stimulation (Fig. 4.1B).  rhPRG4 was rapidly internalized by OA FLS and the 
mechanism of its internalization was related to its interaction with CD44.  This was illustrated by 
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a reduction in OA FLS CTCF with an anti-CD44 treatment (Fig. 4.1D & Fig. 4.1E).  Neutralization 
of CD44 receptor did not completely block rhPRG4 uptake by OA FLS (Fig. 4.1E).  Alternatively, 
treatment with an IC antibody did not alter rhPRG4’s uptake by OA FLS (p>0.05; Fig. 4.1E).  
Inhibition of ACTA2 expression by rhPRG4 was reversed by pre-incubation with an anti-CD44 
antibody (p<0.05 for TGF-b1 + rhPRG4 + anti-CD44 versus TGF-b1 + rhPRG4; Fig. 4.1F).  In 
contrast, IC antibody treatment did not alter the magnitude of reduction in ACTA2 expression 
observed with rhPRG4 (Fig. 4.1F). 
4.4.2 CD44 receptor facilitated rhPRG4 uptake by HEK-TGFβ cells and rhPRG4 inhibited 
TGF-β1/Smad pathway activation 
Representative images demonstrate intracellular red fluorescence following the incubation of 
rhodamine-labeled rhPRG4 with HEK-TGFβ cells (Fig. 4.2A).  Antibody-mediated CD44 receptor 
neutralization reduced the intensity of red fluorescence, indicative of reduced rhPRG4 uptake into 
HEK-TGFβ cells (p<0.001 vs. rhPRG4 alone; Fig. 4.2A and Fig. 4.2B).  This effect was specific 
to CD44 receptor, as a non-specific IC antibody pre-incubation did not alter the extent of rhPRG4 
uptake into HEK-TGFβ cells (p>0.05; Fig. 4.2A and Fig. 4.2B).  Further evidence of CD44 
involvement in rhPRG4 uptake by HEK-TGFβ cells is provided by the intracellular co-localization 
of rhPRG4 (red) and CD44 [198] as shown by arrows (yellow color) (Fig. 4.2A).  TGF-β1 
stimulation resulted in Smad3 phosphorylation as shown in representative images (Fig. 4.2C).  
Intense green fluorescence in TGF-β1-stimulated HEK-TGF-β cells indicated the formation of 
pSmad3.  rhPRG4 treatment reduced mean pSmad3 staining intensity subsequent to TGF-β1 
stimulation (p<0.001; Fig. 4.2D).  In addition, rhPRG4 treatment dose-dependently reduced TGF-
β1/Smad pathway activation as shown by a reduction in the formation of SEAP colored product 
(p<0.05 for 100 and 150μg/mL concentrations versus TGF-β1 alone; Fig. 4.2E). 
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4.4.3 TGF-β induced stress fiber and FAs formation in murine fibroblast NIH3T3 cells 
resulting in enhanced cell migration, and these effects were reduced with rhPRG4 treatment 
Representative images highlight that murine TGF-β induced the formation of stress fibers and 
vinculin expression and thus FAs formation in NIH3T3 cells (Fig. 4.3A).  TGF-β increased the 
percentage of stress fiber-positive NIH3T3 cells by ~ 5-folds (p<0.001 against control cells; Fig. 
4.3B), and increased mean cell spread area by ~ 2-folds (p<0.001 against control cells; Fig. 4.3C).  
rhPRG4 treatment reduced the percentage of stress fiber-positive NIH3T3 cells (p<0.001; Fig. 
4.3B) and mean cell spread area (p<0.001; Fig. 4.3C) to control levels.  TGF-β increased the 
number of FAs in NIH3T3 cells by ~ 4-folds (p<0.001; Fig. 4.3D), and the mean size of FAs per 
cell by ~2-folds (p<0.05; Fig. 4.3E).  Likewise, rhPRG4 treatment reduced the number of FAs 
(p<0.001; Fig. 4.3D) and mean FA size (p<0.05; Fig. 4.3E) to control levels.  A functional 
outcome of TGF-β induced stress fiber and FAs formation was the enhanced migration of NIH3T3 
fibroblasts (Fig. 4.3F).  rhPRG4 reduced TGF-β stimulated NIH3T3 fibroblast migration 
(p<0.001; Fig. 4.3G) while rhPRG4 alone did not change basal NIH3T3 fibroblast migration 
(p>0.05 against control; Fig. 4.3G). 
4.4.4 Lack of Prg4 expression in murine synovial fibroblasts was associated with enhanced 
stress fiber formation, FA size and enhanced basal cell migration which was reduced by 
rhPRG4 or anti-CD44 antibody treatments 
Representative images demonstrate enhanced a-SMA and vinculin staining in Prg4-/- synoviocytes 
compared to Prg4+/+ synoviocytes (Fig. 4.4A).  The mean size of FAs was ~ 2-fold higher in Prg4-
/- synoviocytes compared to Prg4+/+ synoviocytes (p<0.001; Fig. 4.4B).  Prg4-/- synoviocytes 
displayed enhanced basal migration compared to Prg4+/+ synoviocytes (p<0.01; Fig. 4.4C and Fig. 
4.4D).  rhPRG4 and anti-CD44 antibody treatments reduced Prg4-/- synoviocyte migration (p<0.01 
for both treatments; Fig. 4.4D) with no significant difference between both treatments (p>0.05). 
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4.4.5 LPS stimulation of macrophages increased active and total TGF-b levels in a 
macrophage and fibroblast co-culture model, induced fibroblast migration and rhPRG4 
treatment reduced fibroblast migration without altering active or total TGF-b levels 
In response to LPS stimulation and co-culture of macrophages (M) and fibroblasts (F), active TGF-
b levels in the macrophage and fibroblast co-culture were higher compared to fibroblasts alone 
(p<0.001; Fig. 4.5A).  Correspondingly, total TGF-b levels in the macrophage and fibroblast co-
culture were higher compared to fibroblasts alone (p<0.001; Fig. 4.5A).  The increase in active 
and total TGF-b levels resulted in enhanced fibroblast migration in the macrophage and fibroblast 
co-culture compared to fibroblasts alone (p<0.001; Fig. 4.5B and Fig. 4.5C).  rhPRG4 treatment 
reduced fibroblast migration in the co-culture model (p<0.001; Fig. 4.5C).  The effect of rhPRG4 
was not mediated by an alteration in active or total TGF-b levels, shown by the lack of differences 
in active or total TGF-b concentrations between rhPRG4-treated and untreated cells (p>0.05; Fig. 
4.5D). 
4.4.6 Lack of Prg4 expression resulted in progressive synovial tissue fibrosis, shown by 
enhanced a-SMA, collagen type-I and PLOD2 production and Prg4 re-expression reduced 
synovial tissue fibrosis and this effect was evident in CD44-deficient mice 
Synovial tissues from Prg4GT/GT animals displayed higher ACTA2, COL1A1 and PLOD2 
expression levels compared to Prg4 wildtype synovia (p<0.001 for all comparisons; Fig. 4.6A, 
Fig. 4.6D and Fig. 4.6G).  Interestingly, lack of Prg4 expression resulted in a greater increase in 
ACTA2 expression compared to COL1A1 and PLOD2 (p<0.001 for all comparisons).  The 
expression of fibrotic markers in synovial tissues from Prg4GT/GT animals progressed with age.  
ACTA2, COL1A1 and PLOD2 expression levels in 9 months-old Prg4GT/GT animals were higher 
than corresponding expression levels in 2 months-old Prg4GT/GT animals (p<0.001 for all 
comparisons).  The regulation of fibrotic gene expression in the synovium by PRG4 was further 
confirmed by the reduction in ACTA2, COL1A1 and PLOD2 expression in 9 months-old 
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Prg4GTR/GTR animals compared to age-matched Prg4GT/GT animals (p<0.001 for all comparisons).  
Representative images of synovial tissues stained for a-SMA, collagen type-I and PLOD2 proteins 
are shown in Figures 4.6B, 4.6E and 4.6H.  There was no significant difference in mean collagen 
type-I staining intensity between 2 months-old Prg4GT/GT and age-matched Prg4GTR/GTR animals 
(p>0.05; Fig. 4.6F).  Alternatively, mean a-SMA, collagen type-I and PLOD2 staining intensities 
were lower in 9 months-old Prg4GTR/GTR animals compared to age-matched Prg4GT/GT animals 
(p<0.05 for all comparisons; Fig. 4.6C, Fig. 4.6F and Fig. 4.6I).  
The contribution of CD44 to PRG4’s effect on a-SMA and PLOD2 expression was further studied 
in vivo by comparing histological staining intensities in synovial tissues from Cd44+/+&Prg4GT/GT, 
Cd44-/-&Prg4GT/GT, and Cd44-/-&Prg4GTR/GTR (Fig. 4.7).  While mean α-SMA staining intensity 
trended higher in Cd44-/-&Prg4GT/GT synovia compared to Cd44+/+&Prg4GT/GT synovia, this 
increase did not reach statistical significance (p=0.16).  Mean α-SMA staining intensity in Cd44-
/-&Prg4GTR/GTR synovia was lower than corresponding mean intensity in Cd44-/-&Prg4GT/GT 
synovia (p<0.05).  The absence of CD44 receptor increased PLOD2 staining in synovial tissues as 
evidenced by a higher mean staining intensity in Cd44-/-&Prg4GT/GT animals compared to 
Cd44+/+&Prg4GT/GT animals (p<0.001).  In addition, Prg4 re-expression reduced mean PLOD2 
staining in otherwise Cd44 null animals (p<0.001).          
4.5 DISCUSSION 
PRG4, also called lubricin and superficial zone protein, is a mucinous glycoprotein with a protein 
core of 1,404 amino acids and a central mucin domain that is extensively glycosylated with O-
linked b (1-3) Gal-GalNAc oligosaccharides [195, 217, 225, 226].  PRG4 is secreted from synovial 
fibroblasts and superficial zone chondrocytes and is found adsorbed on articular surfaces and the 
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synovial membrane in addition to its presence in SF [168, 227].  PRG4 has a multifaceted role in 
the joint and one aspect of its role is to provide boundary lubrication, to prevent friction-induced 
mitochondrial dysregulation and chondrocyte apoptosis [228-230].  Synthesis of PRG4 by 
cartilage and synovium was reduced in posttraumatic OA (PTOA) animal models and 
inflammatory cytokines e.g. IL-1b reduced PRG4 secretion by synovial fibroblasts while TGF-b 
produced an opposite effect [184, 231, 232].  Furthermore, SF PRG4 levels decreased following 
acute joint trauma and in patients with advanced OA and rheumatoid arthritis (RA) [233-235].  
Therapeutically, native and rhPRG4 demonstrated disease-modifying activities in pre-clinical 
PTOA mediated by their ability to reduce cartilage degeneration, enhance cartilage repair and 
reduce chondrocyte apoptosis [179, 236-238]. 
In this investigation, we studied the role of CD44 in mediating rhPRG4’s antifibrotic and 
antimigratory biological effects on fibroblasts in response to exogenously introduced recombinant 
TGF-b or TGF-b produced by co-cultured macrophages in response to TLR4 receptor stimulation.  
We identified that PRG4 and HA provide a similar outcome in TGF-b stimulated OA FLS in the 
form of preventing transition of fibroblasts to myofibroblasts with inhibition of a-SMA expression 
and thus stress fiber formation.  PRG4 and HA produced an antifibrotic effect in OA FLS using 
concentrations that are well below what is normally found in SF [233-235].  As HA is the 
prototypical CD44 ligand, we used HA as a positive control and our findings support that CD44 
modulates fibroblast to myofibroblast transition in OA synoviocytes.  PRG4 was rapidly 
internalized by OA FLS, with a prominent role for CD44 in this process.  However, CD44 was not 
the only mechanism by which OA synoviocytes internalized rhPRG4 as approximately 60% of 
rhPRG4 entry was blocked subsequent to CD44 receptor neutralization.  CD44-mediated 
rhPRG4’s uptake partially contributed to the latter’s antifibrotic role as rhPRG4’s effect on α-SMA 
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expression was significantly weakened, but not completely abolished, when CD44 mediated 
uptake was blocked.   This indicates that CD44 engagement by rhPRG4 is biologically significant 
in the context of rhPRG4’s antifibrotic effect but does not completely account for the manner in 
which rhPRG4 interacts with synoviocytes.  CD44 also played a role in facilitating the enhanced 
migration of murine synovial fibroblasts that lack Prg4 expression as antibody-mediated 
neutralization of the receptor reduced cell migration.  This finding is consistent with our prior 
observation that Prg4 null synoviocytes had higher CD44 receptor expression levels compared to 
Prg4 competent synoviocytes and is supported by an independent finding that CD44 plays a role 
in facilitating cell migration [127, 154, 236].  Synovial fibrosis developed in Prg4 null mice and 
expression of SMA, PLOD2 and collagen type-I progressively increased as animals aged.  
Interestingly, the in vivo antifibrotic effect due to Prg4 re-expression was not dependent on CD44 
as endogenously produced PRG4 reduced SMA and PLOD2 expression in Cd44 null animals.  
CD44 is a single-pass transmembrane glycoprotein that is widely expressed in immune and 
connective tissues, and different isoforms, generated by alternate splicing, have been characterized 
[127, 236].  The extracellular domain of CD44 binds different ligands and thus can sense a broad 
array of microenvironmental signals resulting in ligand-specific effects in inflammation, cell 
migration and growth [239-241].  In addition to HA and PRG4, other CD44 ligands include 
osteopontin, chondroitin, fibronectin, and matrix metalloproteinases (MMPs) [239, 242].  The 
intracellular domain of CD44 lacks intrinsic kinase activity, but it transduces extracellular ligand-
specific signals via a combination of proteolytic fragmentation or interactions with different 
signaling pathways including members of Src and Ras family of GTPases and protein phosphatase-
2A [239, 243, 244].   HA is cellularly uptaken by CD44, and this interaction mediates HA’s ability 
to suppress MMP-13 and aggrecanase-1 expression in OA chondrocytes and synoviocytes [128, 
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245, 246].  In addition to inhibiting synovitis, HA treatment inhibited synovial fibrosis in a murine 
model of TGF-b and treadmill running [128, 247, 248].  The effect of HA was CD44-dependent 
as its antifibrotic effect was abolished in CD44-deficient mice [247].  Contrary to HA, PRG4 had 
an in vivo antifibrotic effect that was not dependent on CD44.  This might be related to PRG4’s 
ability to regulate other signaling pathways apart from CD44.  PRG4 binds to and inhibits the 
activation of TLR2 and TLR4 receptors by their ligands and by SF aspirates from patients with 
OA [249, 250].  In addition, PRG4 was internalized by murine macrophages and co-localized with 
both CD44 and to lesser extent TLR2 receptors in the cytosol of these cells [251].  As such, it is 
expected that the enhanced TLR2 and TLR4 receptor signaling in the absence of PRG4 would 
propagate synovitis in Prg4 null mice.  The innate immune-mediated synovitis would in turn 
contribute to the development of synovial fibrosis.  Upon Prg4 re-expression in 3-weeks old 
animals, PRG4 would attenuate TLR2 and TLR4 mediated synovitis, thereby potentially reducing 
TLR-regulated fibrotic tissue remodeling [252].           
Myofibroblasts are characterized by a-SMA expression, stress fiber and FAs formation and are 
thought to play an effector role in the pathophysiology of tissue fibrosis [252, 253].  Compared to 
fibroblasts, myofibroblasts produce more collagen; respond to mitogenic signals resulting in cell 
proliferation, migration and secretion of matrix-degrading enzymes [190, 252].  While stress fibers 
and FAs are unique structures within the cell, they are highly interconnected, where they 
coordinate cell responses to mechanical signals in their microenvironment [254].  Interestingly, 
the mean size of FAs, and not their molecular composition or density, can accurately predict cell 
migration [255].  Normal synovial fibroblasts do not appear to express a-SMA, even with TGF-b 
stimulation [191].  In our study, OA FLS had a basal level of a-SMA expression and in response 
to TGF-b, a-SMA expression was enhanced and stress fibers appeared.  This was also evident in 
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murine NIH3T3 fibroblasts as the transition from a fibroblast to a myofibroblast phenotype was 
accompanied by stress fiber and FAs formation, with subcellular and cellular changes in the form 
of increased number and mean size of FAs and cell spread area and thus enhanced cell migration.  
rhPRG4 acted biologically to reduce the formation of stress fibers and to reduce the mean number 
and size of FAs in NIH3T3 fibroblasts and this reduction resulted in inhibition of fibroblast 
migration.  Thus, it is unlikely that the observed antimigratory effect of rhPRG4 was a physical 
effect consequent to PRG4’s amphipathic nature and its adsorption on hydrophilic and 
hydrophobic surfaces [198].  The higher mean size of FAs in synoviocytes from Prg4 null mice, 
and its resultant enhanced migration argues that PRG4 plays a role in regulating the expression of 
the cellular machinery mediating migration in vivo.  This may have a biological relevance in the 
realm of synovial fibrosis where PRG4 may function to reduce the migration of fibrocytes to the 
inflamed joint and therefore the likelihood of adding to the pool of existing myofibroblasts in the 
synovium [256, 257].    
Synovial tissue macrophages are critical regulators of the initiation, maintenance and resolution 
phases of synovitis [258].  The complex functions of macrophages are enabled by the presence of 
different macrophage subpopulations within the joint, which fulfill distinct inflammatory and 
antiinflammatory roles [258].  In synovial tissue fibrosis, bone marrow derived monocytes and 
macrophages are found in increased numbers, which may signal their involvement in the 
development of synovial fibrosis [259, 260].  In response to an inflammatory signal, macrophages 
produce TGF-β as a regulatory feedback signal to aid in the resolution of inflammation [261, 262].  
TGF-β in turn triggers myofibroblast differentiation and production of matrix proteins [220].  In 
our study, LPS stimulation resulted in increased secretion of TGF-β by macrophages.  Cells secrete 
a latent form of TGF-β, which in turn is proteolytically converted to active TGF-β by a variety of 
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proteases, including MMPs [263].  The generation of active TGF-b in the co-culture system was 
associated with fibroblast migration.  Interestingly, the introduction of rhPRG4 after macrophage 
activation did not alter total TGF-β quantity produced by macrophages.  Furthermore, rhPRG4 did 
not alter the rate of activation of latent TGF-β, indicating that the antimigratory effect of rhPRG4 
was at the level of fibroblasts’ response to TGF-b receptor activation.  This is supported by our 
observation that rhPRG4 reduced Smad3 phosphorylation in TGF-β reporter cells and that 
reduction in pSmad3 intracellular levels attenuated the TGF-β/Smad pathway activation.  In TGF-
β reporter cells, the attenuation of Smad signaling pathway was downstream to rhPRG4 uptake by 
these cells in a mechanism that involved CD44 receptor, similar to what was observed in OA FLS.  
However, the precise mechanism that is activated by CD44 engagement that inhibits TGF-β/Smad 
signaling pathway remains unclear.  Another limitation of our study was that we did not study the 
antifibrotic effect of rhPRG4 in vivo. 
4.6 CONCLUSION 
In summary, we demonstrated that PRG4 is an important regulator of synovial tissue fibrosis using 
a combination of in vitro and in vivo models.  PRG4 prevented the transition of human and murine 
fibroblasts to a myofibroblast phenotype and in OA FLS; the mechanism of PRG4’s antifibrotic 
effect was partially linked to CD44-mediated cell uptake.  rhPRG4 acted biologically to reduce 
Smad3 phosphorylation, the activation of TGF-β/Smad signaling pathway, and FA mean size 
which translated to inhibiting fibroblast migration.  The lack of Prg4 expression in murine synovial 
tissues resulted in enhanced expression of SMA, collagen type-I and PLOD2, the enzyme 
responsible for collagen cross-linking.  Synovial fibrosis in Prg4GT/GT animals progressed with age 
and re-establishing Prg4 expression was antifibrotic.  The role of PRG4 in regulating synovial 
fibrosis in vivo extends beyond its interaction with CD44 receptor, as Prg4 re-expression was 
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antifibrotic in Cd44 null mice.  Therapeutically, overexpressing PRG4 in the articular joint, using 
a viral mediated gene delivery approach, may prove beneficial in reducing synovial fibrosis in 
addition to reducing cartilage degeneration [264, 265].  The study of PRG4 as an antifibrotic 
modulator of the joint’s soft tissues is further warranted especially with the known contribution of 
synovial fibrosis in advanced OA.  
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4.15 Figures 
 
 
Fig. 4.1 Impact of proteoglycan-4 (PRG4) and high molecular weight hyaluronic acid (HA) 
treatments on TGF-β1 induced alpha smooth muscle actin (α-SMA) expression (ACTA2), 
production and stress fiber formation in fibroblast-like synoviocytes isolated from patients with 
OA (OA FLS) undergoing knee replacement surgery and CD44-dependent uptake of rhodamine-
labeled recombinant human PRG4 (rhPRG4) into OA FLS and associated regulation of ACTA2 
expression.  OA FLS were treated with TGF-β1 (1 ng/mL) ± rhPRG4 (~240 kDa) or HA (~1,200 
kDa) (100μg/mL for both treatments) for 24 hours followed by RNA isolation and qPCR using 
GAPDH as an internal reference gene.  OA FLS were stained with anti-α-SMA [198] and 
counterstained for α-tubulin (red) and DAPI (blue).  Corrected total cell fluorescence (CTCF) of 
α-SMA was determined following a 48-hour treatment, and normalized to controls.  Rhodamine-
labeled rhPRG4 was incubated with OA FLS ± anti-CD44 or isotype control (IC) antibodies for 
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30 min., and CTFC was quantified.  OA FLS were treated with TGF-β1 ± rhPRG4 ± anti-CD44 
or IC for 24 hours and ACTA2 expression was determined.  Data are presented as a scatterplot with 
means and standard deviations highlighted utilizing OA FLS from 3-4 different patients.  
*p<0.001; ***p<0.05.  Scale=50μm.   
A) PRG4 and HA reduced ACTA2 expression in OA FLS. 
B) Representative images showing TGF-β1 induced stress fiber formation in OA FLS (white 
arrows) and PRG4 or HA treatments prevented their formation. 
C) PRG4 and HA reduced α-SMA CTCF in OA FLS. 
D) Representative images showing rhodemine-rhPRG4 intracellular localization (white arrows), 
following incubation with OA FLS. 
E) Co-incubation of rhPRG4 and anti-CD44 reduced cellular uptake of rhPRG4. 
F) Anti-CD44 antibody co-treatment reduced rhPRG4’s antifibrotic effect in OA FLS. 
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Fig. 4.2 CD44-dependent interaction of recombinant human proteoglycan-4 (rhPRG4) with HEK  
Blue-TGF-b cells and associated modulation of phosphorylated Smad3 (pSmad3) and TGF-
b/Smad signaling pathway.  HEK Blue-TGF-b is an engineered cell line produced by transfecting 
human embryonic kidney (HEK) cells with TGF-b receptor 1 (TGF-b R1), Smad3 and Smad4 
genes.  Activation of TGF-b R1 results in expression of secreted alkaline phosphatase (SEAP) 
whose activity can be determined colorimetrically.  Rhodamine-labeled rhPRG4 was incubated 
with HEK Blue-TGF-b cells ± anti-CD44 or isotype control (IC) antibodies and corrected total 
cell fluorescence (CTCF) was determined.  pSmad3 immunocytostaining was performed using an 
antibody against pSmad3 and pSmad3 fluorescence intensity was determined.  Activity of TGF-
b/Smad pathway was determined colorimetrically.  *p<0.001; **p<0.01; n.s.: non-significant.  
Scale in A=40μm; Scale in C=50μm.    
A) Representative images showing rhPRG4 internalization (white arrows) by HEK-TGF-b 
cells and colocalization with CD44 receptor (white arrows in merged image). 
B) rhPRG4 uptake by HEK-TGF-b cells was reduced by CD44 receptor neutralization. 
C) Representative images showing pSmad3 staining in HEK-TGF-b cells following TGF-b 
stimulation (white arrows) ± rhPRG4 treatment. 
D) pSmad3 immunocytostaining was reduced following rhPRG4 treatment. 
E) rhPRG4 treatment dose-dependently reduced TGF-b/Smad signaling pathway in TGF-b 
stimulated HEK- TGF-b cells. 
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Fig. 4.3 Impact of recombinant human proteoglycan-4 (rhPRG4) treatment on TGF-b induced 
stress fiber formation, vinculin expression, and formation of focal adhesions (FAs) in murine 
fibroblasts (NIH3T3) and its relationship to cell migration.  Stress fiber formation was probed 
using an anti-alpha smooth muscle actin (a-SMA) antibody and a blinded investigator evaluated 
% stress fiber-positive fibroblasts.  Vinculin (a marker of FAs) expression was probed using an 
anti-vinculin antibody and cells were counterstained using rhodamine-labeled phalloidin 
(cytoskeleton label; red).  NIH3T3 Fibroblast migration was performed using a scratch assay and 
the wound closure percentage was determined. *p<0.001; **p<0.01; ***p<0.05; n.s.: non-
significant.  Scale in A and F=20μm;  
A) Representative images showing TGF-b induced stress fiber formation and vinculin staining 
(white arrows) in NIH3T3 fibroblasts. 
B) rhPRG4 reduced stress fiber formation in NIH3T3 fibroblasts. 
C) rhPRG4 reduced mean NIH3T3 fibroblast spread area. 
D) rhPRG4 reduced the number of FAs in NIH3T3 fibroblasts. 
E) rhPRG4 reduced the mean size of FAs in NIH3T3 fibroblasts. 
F) Representative images showing NIH3T3 migration in response to TGF-b ± rhPRG4. 
G) rhPRG4 reduced NIH3T3 migration. 
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Fig. 4.4 Stress fibers and focal adhesions (FAs) in murine synovial fibroblasts isolated from Prg4-
/- and Prg4+/+ mice and their relationship to cell migration.  Stress fiber formation was probed 
using an anti-alpha smooth muscle actin (a-SMA) antibody [198].  Vinculin (a marker of FAs) 
expression was probed using an anti-vinculin antibody [198] and cells were counterstained using 
rhodamine-labeled phalloidin (cytoskeleton label; red).  The impact of rhPRG4 treatment 
(200µg/mL) on basal Prg4-/- synovial fibroblast migration was assessed using the scratch assay 
and the wound closure percentage was determined.  To highlight the CD44-dependency of the 
enhanced basal migration of Prg4-/- synovial fibroblasts, cells were also treated with either an anti-
CD44 or isotype control (IC) antibodies (2µg/mL for both antibodies).  *p<0.001; **p<0.01; n.s.: 
non-significant.  Scale in A=50μm (a-SMA) and 100μm (vinculin); Scale in C=50µm.      
A) Representative images showing increased stress fibers and FAs in Prg4-/- synoviocytes. 
B) Prg4-/- synoviocytes demonstrated a higher mean FA size than Prg4+/+ synoviocytes. 
C) Representative images showing enhanced basal migration of Prg4-/- synoviocytes 
compared to Prg4+/+ synoviocytes. 
D) rhPRG4 and anti-CD44 treatments were equally effective in reducing basal migration of 
Prg4-/- synoviocytes. 
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Fig. 4.5 Impact of co-culturing murine fibroblasts (F) and murine macrophages (M) on active 
and total supernatant TGF-β levels, fibroblast migration and efficacy of rhPRG4 in regulating 
fibroblast migration in the co-culture model.  Murine macrophages (J774A) were stimulated 
with lipopolysaccharide (LPS; 5µg/mL) for 24 hours prior to seeding in the top chamber of a 
co-culture system.  Murine fibroblasts (NIH3T3) were cultured in the lower chamber of the 
same system.  Active and total TGF-β media levels were determined using an ELISA.  A 
scratch was performed in the fibroblast monolayer and fibroblast migration in the lower 
chamber was determined at 48 hours ± rhPRG4 (200µg/mL). *p<0.001; **p<0.01; n.s.: non-
significant.  Scale =40µm.  
A) Active and total TGF-β concentrations were higher in the fibroblast and macrophage 
co-culture compared to fibroblasts alone.   
B) Representative images of fibroblast migration across different experimental groups.  
Fibroblast migration was highest in co-cultured fibroblasts and macrophages and rhPRG4 
treatment reduced fibroblast migration.   
C) rhPRG4 reduced fibroblast migration in a fibroblast and macrophage co-culture 
model.   
D) rhPRG4 did not alter active or total TGF-β media levels in the fibroblast and 
macrophage co-culture model.  
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Fig. 4.6 Gene expression and immunohistological analysis of fibrotic markers: alpha smooth 
muscle actin (a-SMA) (ACTA2), collagen type-1 (COL1A1) and procollagen-lysine, 2-
oxoglutarate 5-dioxygenase (PLOD2) in synovial tissues isolated from 2- and 9-months old gene-
trap (Prg4GT/GT) and 2 and 9 months old recombined gene-trap (Prg4GTR/GTR) mice.  The Prg4 gene-
trap allele is a loss of function allele (Prg4GT/GT) whose function is restored with Cre-excision 
(Prg4GTR/GTR).  Recombination occurred at 3 weeks of age using intraperitoneal tamoxifen (0.1 
mg/g in 100µL corn oil vehicle) daily for 10 days.  Fibrotic markers were probed using specific 
antibodies and staining intensities (lumens per mm2) were quantified.  *p<0.001; **p<0.01; 
***p<0.05.  Scale=100µm.    
A) ACTA2 expression was higher in 9 months Prg4GT/GT compared to 2 months littermates and 
was reduced by Prg4 re-expression.  
B) Representative images showing enhanced α-SMA immunostaining in 2 and 9 months Prg4GT/GT 
synovia.  
C) Prg4 re-expression reduced α-SMA content in 2 and 9-months old animals.  
D) COL1A1 expression was higher in 9 months old Prg4GT/GT animals compared to 2 months and 
was reduced by Prg4 re-expression.  
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E) Representative images showing enhanced collagen type I immunostaining in 9 months old 
Prg4GT/GT synovia.  
F) Collagen type I content was higher in 9 months old Prg4GT/GT animals and was reduced with 
Prg4 re-expression.  
G) PLOD2 expression was higher in 9 months old Prg4GT/GT animals compared to 2 months and 
was reduced by Prg4 re-expression.  
H) Representative images showing enhanced PLOD2 immunostaining in Prg4GT/GT synovia.  
I) Prg4 re-expression reduced PLOD2 content in Prg4GT/GT synovia in 2- and 9-months old 
animals. 
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Fig. 4.7 Modulation of expression of fibrotic markers: alpha smooth muscle actin (a-SMA) and 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD2) in synovial tissues from Prg4 gene-
trap animals by CD44.  The Prg4 gene-trap allele is a loss of function allele (Prg4GT/GT) whose 
function is restored with Cre-excision (Prg4GTR/GTR).  Prg4GT/GT animals were crossed with Cd44-
/- mice to generate PrgGT/GT&Cd44-/- animals.  Recombination occurred at 3 weeks of age using 
intraperitoneal tamoxifen (0.1 mg/g in 100µL corn oil vehicle) daily for 10 days.  Fibrotic markers 
were probed using specific antibodies and staining intensities (lumens per mm2) were quantified.  
Prg4 recombination reduced a-SMA and PLOD2 staining in synovial tissues of 2-months old 
Cd44+/+ and Cd44-/- animals.  *p<0.001; ***p<0.05; n.s.: non-significant.   
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5 CHAPTER 5 
SUMMARY AND CONCLUSION   
In chapter 2, given the importance of CD44 in OA pathogenesis, and the emerging evidence of a 
biological role for HA, we aimed to evaluate the role of CD44 in regulating NF-kB activation and 
proinflammatory cytokine production in response to TLR2 receptor activation in human 
macrophages, using a combination of CD44 receptor knockdown, TNF-α production by 
macrophages from CD44 wildtype and knockout mice, and CD44 receptor engagement by CD44-
neutralizing Ab and HA treatments.  HA is produced by fibroblast-like synoviocytes and is a major 
component of the synovial fluid (SF).  HA exerts important functions in the joint and its biological 
effects are mediated by its binding to its transmembrane receptor, CD44.  In this work, we found 
that Anti-CD44 Ab and HA treatments reduced NF-kB translocation, IL-1b and TNF-α expression, 
and production.  Inhibition of proinflammatory response in macrophages by HA was mediated by 
CD44. Protein phosphatase 2A mediated the reduction in NF-kB translocation by HA. CD44 
knockdown reduced NF-kB nuclear translocation and downstream IL-1b and TNF-α protein 
production following TLR2 receptor stimulation. Cd44+/+ murine bone marrow–derived 
macrophages produced higher TNF-α compared with Cd44-/- macrophages following TLR2 
stimulation. HA dose-dependently inhibited TLR2-induced TNF-α production by murine bone 
marrow–derived macrophages.  OA SF stimulated TLR2 and TLR4 receptors and induced NF-kB 
translocation in human macrophages. Anti-CD44 Ab treatment significantly reduced macrophage 
activation by OA SF. CD44 regulated TLR2 responses in human macrophages, whereby a 
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reduction in CD44 levels or engagement of CD44 by its ligand (HA) or a CD44-specific Ab 
reduced NF-kB translocation and downstream proinflammatory cytokine production. A CD44-
specific Ab reduced macrophage activation by OA SF, and CD44 is a potentially novel target in 
OA treatment.  
In chapter 3, we investigated the antifibrotic efficacy of forskolin, an adenylyl cyclase activator 
that increases intracellular cAMP, in a model of TGF-β stimulated osteoarthritic fibroblast-like 
synoviocytes (OA-FLS). Synovial fibrosis is characterized by excess extracellular collagen I, 
TIMP-1 and PLOD2 expression and FLS proliferation and migration.  A myofibroblast-like 
differentiation of synoviocytes, characterized by alpha smooth muscle actin (α-SMA) expression, 
is associated with synovial fibrosis.  Synoviocytes secrete HA and proteoglycan-4 (PRG4).  HA 
and PRG4 may be linked to synovial fibrosis.  Collagen I (COL1A1), α-SMA, TIMP-1, PLOD2 
expression and procollagen I, α-SMA, HA and PRG4 production, migration and proliferation of 
OA-FLS were studied in TGF-β ± forskolin-treated OA-FLS. The antifibrotic effect of HA and 
PRG4 was investigated using OA-FLS and Prg4-/- synoviocytes, and fibrosis markers were 
evaluated in Prg4+/+ and Prg4-/- synovial tissues.  Forskolin (10μM) reduced COL1A1, α-SMA 
and TIMP-1 expression, with no change in PLOD2 expression.  Forskolin (10-30μM) reduced 
procollagen I, α-SMA and OA-FLS migration and proliferation.  Forskolin (10μM) increased HA 
secretion, PRG4 expression and production.  HA and synoviocyte PRG4 reduced α-SMA 
expression and content.  PRG4 reduced COL1A1 expression and procollagen I content.  Prg4-/- 
synovial tissues exhibited increased α-SMA, COL1A1 and TIMP-1 expression compared to 
Prg4+/+ tissues.  Prg4-/- synoviocytes demonstrated strong α-SMA and collagen type I staining 
with none detected in Prg4+/+ synoviocytes and PRG4 treatment reduced cellular staining for both 
proteins.  Clinical significance: OA synovial fibrosis can be mitigated by therapeutically increasing 
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intracellular cAMP in synovial fibroblasts with an associated enhancement of HA and PRG4 
production.  
In chapter 4, we demonstrated that PRG4 is an important regulator of synovial tissue fibrosis 
using a combination of in vitro and in vivo models.  PRG4 prevented the transition of human and 
murine fibroblasts to a myofibroblast phenotype and in OA FLS; the mechanism of PRG4’s 
antifibrotic effect was partially linked to CD44- mediated cell uptake.  rhPRG4 acted biologically 
to reduce Smad3 phosphorylation, the activation of TGF-β/ Smad signaling pathway, and FA mean 
size which translated to inhibiting fibroblast migration.  rhPRG4 inhibited fibroblast migration in 
a macrophage and fibroblast co-culture model without altering active or total TGF-β levels. The 
lack of Prg4 expression in murine synovial tissues resulted in enhanced expression of SMA, 
collagen type-I, and PLOD2, the enzyme responsible for collagen cross-linking.  Synovial fibrosis 
in Prg4GT/GT animals progressed with age and re-establishing Prg4 expression was antifibrotic. 
The role of PRG4 in regulating synovial fibrosis in vivo extends beyond its interaction with CD44 
receptor, as Prg4 re-expression was antifibrotic in Cd44 null mice. Therapeutically, 
overexpressing PRG4 in the articular joint, using a viral mediated gene delivery approach, may 
prove beneficial in reducing synovial fibrosis in addition to reducing cartilage degeneration. The 
study of PRG4 as an antifibrotic modulator of the joint’s soft tissues is further warranted especially 
with the known contribution of synovial fibrosis in advanced OA.  
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